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ABSTRACT 
DIET, PREBIOTICS, AND PROBIOTICS: EFFECTS ON GUT MICROBIOTA IN 
OBESITY AND METABOLIC DISORDERS 
THAMER ALJUTAILY 
2019 
 Targeting gut microbiota with diet, prebiotics, and probiotics are emerging as a 
promising intervention in the comprehensive nutritional approach to reducing obesity and 
metabolic disorders. Recent human and animal studies suggest that such intervention can 
promote health benefits by influencing the aspects of metabolism and immunity. 
However, study of the multi-role association between the diet, the host and the 
microbiota remains to be clarified. My dissertation attempts to clarify the problem of how 
gut microbiota (taxonomic composition and predicted functional capacities) affects 
obesity and metabolic disorders. 
 In chapter 2, I conducted a placebo-controlled intervention clinical trial to 
evaluate effects of a synbiotic supplement containing Bifidobacterium and Lactobacillus 
strains on the human gut microbiota in relation to changes in body composition and 
metabolic biomarkers in obesity, followed the weight loss program eating plan (a low-
carbohydrate, high-protein dietary pattern with reduced energy intake). The results 
obtained and bioinformatic analysis support the conclusion that the synbiotic supplement 
used in this study modulates the human gut microbiota by increasing abundance of 
beneficial microbial genera and that the supplement may also have beneficial effects on 
metabolic parameters in obesity. 
xvii 
 
 In chapter 3, I characterized the effect of dairy products (cow, goat, and camel 
milk and fermented cheese and yogurt originated from cow milk and containing the well-
established probiotic Clostridium butyricum) on taxonomic composition and relative 
abundance of the mouse gut microbiota and body weight. The results obtained and their 
bioinformatics analysis appear to support the conclusion that camel milk and the 
probiotic cow cheese induce changes the mouse gut microbiota, which are associated 
with the optimal weight gain in growing mice. 
 In chapter 4, I evaluate the effect of food at home (FAH) and food away from 
home (FAFH) diets on human gut microbiota. Substantial work has been done to study 
whether the FAH diet-induced microbial and immunity changes can protect mice against 
diabetes. The results obtained and their analysis suggest that the FAH can help to reduce 
risk of developing diabetes by increasing abundance of potentially beneficial microbial 
species, T regulatory cells, and decreasing IL-17 producing cells and blood glucose 
levels. 
 This dissertation explores a scope of studies on the effects of diet on gut 
microbiota and health outcomes including obesity and metabolic disorders taking into 
perspective diets such as food at home, dairy products, high-protein, low-carbohydrate, 
prebiotic and probiotic. The main outcome of our studies is identification of an effective 
and novel approach for the prevention and treatment of obesity and metabolic disorders 
that is based on modulating the human/mouse gut microbiota and increasing abundance 
of the microbial species that can be considered to be of benefit to their immune system 
and host.
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CHAPTER 1. Introduction and Literature Review 
The rising prevalence of obesity and metabolic disorders and its harmful health 
consequences are of increasing global concern [1, 2]. Recent studies have implicated the 
gut microbiota (a dynamic and complex population of microbes that live in the 
gastrointestinal tract) in contributing to this epidemic [3-5]. However, advances in “next 
generation” DNA sequencing have dramatically increased our capacity to study microbial 
communities associated with human body habitats (microbiota) [6, 7]. Subsequent studies 
revealed that gut microbiota influence caloric intake, intestinal absorption, energy 
balance, and immunological status, therefore strategies aiming at modulating the 
microbiota to control obesity and metabolic disorders are the focus of considerable 
attention [8, 9]. Indeed, recent studies have shown that certain prebiotics and probiotics 
(both diet-based processes that can be used to increase health of the host by enhancing 
the composition of colonic microbiota) have been successful in promoting weight-loss in 
diet-induced obesity or diabetes [10, 11]. 
Importantly, the gut microbiota provides the human host with a number of 
benefits besides energy extraction, including vitamin synthesis and a reduction of low-
grade chronic inflammation associated with obesity and metabolic disorders [12, 13]. 
Therefore, a healthy and diverse gut microbiota is critical for the well-being of the host 
[14, 15]. Consequentially, a gut microbiota intervention (either pre- or probiotics or a 
synbiotic treatment) in individuals suffering a microbial dysbiosis from obesity or severe 
diets may provide beneficial effects behind weight loss (Figure 1-1). 
In these studies, human obese subjects and mouse model were used to test the 
hypothesis that the specific diets, prebiotics and probiotics used in these studies will 
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modulate the gut microbiota by increasing abundance of the beneficial microbial species, 
T regulatory cells, and decreasing in inflammation-associated bacteria, IL-17 producing 
cell populations, and the supplement may also have beneficial effects on body 
composition and metabolic parameters in obesity. Three specific aims have been 
designed to test this hypothesis. 
AIM 1. To evaluate effects of the synbiotic supplement containing Bifidobacterium and 
Lactobacillus strains on the human-gut microbiota in relation to changes in body 
composition and metabolic biomarkers in obesity. 
AIM 2. To characterize the effects of probiotic-enriched pasteurized milk, Greek-style 
yogurt, and cottage cheese made from milk of different origins (cow, goat, and camel) on 
the taxonomic composition of the mouse gut microbiota and body weight. 
AIM 3. To study the effects of food at home and food away from home diets on human 
gut microbiota. In addition, to study whether the food at home-diet-induced microbial and 
immunity changes can protect mice against diabetes. 
3 
 
 
 
Figure 1-1. Importance of balanced nutrition and gut microbiota. There are shifts in the 
composition of the microbiota (dysbiosis) whereby either the numbers of 
Beneficial/Commensal are reduced and/or Harmful/Opportunistic are increased. Several 
causes (i.e., dietary shifts, sedentary habits, high-fat diet, and antibiotic abuse) can trigger 
this change and result in non-specific inflammation which can lead to diabetes, obesity, 
and inflammatory diseases. Healthy diet and lifestyle, whole grains, dairy products and 
prebiotic/probiotic supplements can reverse this inflammatory status to a healthy anti-
inflammatory environment.  
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Literature Review 
The part (1.1.3) included in this literature review have been previously published in the 
Cellular & Molecular Immunology: 
Aljutaily, T., Consuegra-Fernández, M., Aranda, F., Lozano, F., & Huarte, E. (2018). Gut 
microbiota metabolites for sweetening type I diabetes. Cellular & molecular 
immunology, 15(2), 92–95. PMID: 28757611. Impact Factor (2018), 8.21; Ranking 
(2018), 14/158 in Immunology. 
1.1.1 Early mice studies 
A causal link between gut microbiota and obesity was initially suggested based on 
studies with germ free (GF) mice. Because gut microbiota has the capacity to ferment 
otherwise-indigestible dietary compounds, and thus increase energy extraction from 
foods, GF mice are leaner than conventional mice. However, they rapidly expand their fat 
mass and increase insulin resistance after colonization with cecal microbiota from 
conventional mice despite reduce food intake [16, 17]. Subsequent studies demonstrated 
that colonization of GF mice with cecal microbiota from obese mice resulted in a greater 
increase in body fat when compared with microbiota transplants from lean mice [18, 19], 
thus demonstrating that an “obese microbiota” has an increased capacity to harvest 
energy from the diet, and thus was responsible, and not just the consequence, of 
metabolic disease and obesity. A more recent study where GF mice were colonized with 
fecal samples obtained from adult female twin pairs discordant for obesity confirmed the 
capacity of certain bacterial communities to increase total body and fat mass, as well as 
obesity-associated metabolic phenotypes. Importantly, the study also demonstrated that 
the induced metabolic disease was reversible when mice were exposed to a “lean 
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microbiota” and dependent on the diet [20], thus confirming transmissible, rapid and 
modifiable effects of diet by microbiota interactions and opening the door to microbiota 
modification strategies as a therapy against obesity and metabolic disease. 
1.1.2 Human gut microbiota 
 Human beings host trillions of microbes from all domains of life (eukaryota, 
bacteria, virus and archaea) on multiple surfaces, with the highest density and diversity 
located on the colon, where bacteria cells are present in concentrations of 109-1012 per ml 
[21]. While the diversity of the gut microbiota is mind-blowing (averaging more than 
1000 different species with an aggregate of approximately 0.5 million genes per human 
host), up to 90% of the bacterial species belong to just 2 phyla: Firmicutes and 
Bacteroidetes [22, 23]. Originally, a higher proportion of Bacteroidetes over Firmicutes 
have been correlated with a leaner status both in mice and humans [24]. Recent studies, 
however, focus on characterizing the microbiota at the species and strain levels, allowing 
for finer associations between microbiota and weight. Despite the large inter-individual 
(and even intra-individual) variation in the gut microbiota, it has also been suggested that 
individuals can be assigned to one of just 3 different metagenomics profiles (called 
enterotypes), dominated by either Bacteroides, Prevotella or Ruminococcus, of which 
Bacteroides and Ruminococcus are often associated with a low-grade persistent 
inflammation, obesity and metabolic disease [25, 26]. 
1.1.3 Gut microbiota metabolites and type I diabetes 
 Type 1 diabetes (T1D), also referred to as insulin-dependent diabetes mellitus, is a 
debilitating disease that follows the destruction of pancreatic insulin-producing β cells by 
autologous T-cells. T1D primarily affects children and has a strong genetic component, 
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with >50 susceptibility loci identified, including HLA-DQβ chains [27]. However, the 
striking differences between European regions with similar genetic backgrounds and a 
sharp rise in T1D incidence in developed countries over the last several decades suggest 
that environmental factor(s) also play a relevant etiopathogenic role [28]. Given the 
accumulating evidence linking the gut microbiota to protection against metabolic diseases 
[29], Mariño et al. recently tested the hypothesis that short-chain fatty acids (SCFAs), 
which are the end products of fermentation of dietary fibers by anaerobic intestinal 
microbiota, can protect genetically susceptible mice from developing T1D [30]. 
Interestingly, the authors found that diets enriched in acetate or butyrate (two of the main 
SCFAs) can protect animals from developing diabetes through different and 
complementary cellular mechanisms. Such findings significantly enhance our 
understanding of the role of diet and gut microbiota in the development of autoimmune 
diseases and indicate that the use of medicinal foods may be a cost-effective treatment 
against T1D and other autoimmune diseases with a cellular component. Given that 
current anti-T1D approaches (which focus on prevention or modulation of the adaptive 
specific immune response against autoantigens) have been generally disappointing [31], 
such a new and refreshing strategy has attracted a great deal of attention (reviewed in 
Ref. [28]). 
 Over the last decade, an ever-growing body of evidence has established that the 
gut microbiota is one of the most important epigenetic determinants of prevalent 
metabolic disorders such as type 2 diabetes and metabolic syndrome [32]. Similarly, 
accumulating experimental observations indicate that T1D incidence in non-obese 
diabetic (NOD) mice is influenced by the microbial environment, thus indicating that the 
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gut microbiota is involved in T1D development [33]. This concept has been well 
illustrated by a recent report demonstrating that the interaction between the gut 
microbiota and the host immune system was essential for the prevention and treatment of 
T1D [34]. In their study, Wen et al. generated myeloid differentiation primary response 
88 (MyD88)-deficient mice in a NOD background (NOD.Myd88−/−). MyD88 is a master 
regulator of immune responses and is capable of detecting bacteria and other infectious 
agents by binding to Toll-like receptors and initiating a pro-inflammatory cascade 
dependent on nuclear factor kappa beta (NF-κB) activation. NOD.Myd88−/− mice kept 
under specific-pathogen free conditions were completely protected against T1D 
development, but this protection was dependent on commensal microbiota, as 
NOD.Myd88−/− mice housed in germ-free (GF) conditions developed robust diabetes. 
Importantly, when these animals were colonized with altered Schaedler’s flora, which is a 
consortium of six bacteria that are normally found in the human gut, protection against 
T1D was restored. Molecular analyses of cecal microbiota revealed that MyD88 ablation 
correlates with changes in the microbiota composition, with a significant increase in 
butyrate-producing Firmicutes, as well as Rikenellaceae and Porphoromadaceae. 
 SCFA (namely, acetate, butyrate and propionate) are the main metabolites of the 
bacterial fermentation of dietary fiber and have been associated with anti-inflammatory 
effects via the up-regulation of regulatory T (Treg) cells and the inhibition of histone 
deacetylase (HDAC) activity [35]. Given the instrumental role of SCFA in intestinal 
homeostasis, Mariño et al. compared the SCFA concentration in diabetes-prone NOD 
mice and their diabetes-resistant NOD.Myd88−/− counterparts. Although the propionate 
levels were similar between both mouse lines, the acetate and butyrate levels were much 
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higher in the NOD.MyD88−/− animals, which suggested that T1D protection was 
mediated by SCFAs. In addition, T1D-prone NOD mice under GF conditions developed a 
more aggressive form of the disease, thus supporting the role of commensal bacteria-
produced metabolites as a defense mechanism against diabetes (Figure 1-2). 
 
Figure 1-2. Main experimental approach revealing the specific mechanisms of acetate 
and butyrate protection in T1D development. (a) NOD mice undergo exacerbated T1D in 
germ-free (GF) conditions. Oral administration of acetylated high-amylose maize starch 
(HAMSA) or butyrylated high-amylose maize starch (HAMSB) increased acetate or 
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butyrate concentrations, respectively, which protected NOD mice from T1D development 
via independent mechanisms. Whereas HAMSA administration reduced specific IGRP 
(islet-specific antigen glucose-6-phospatase catalytic subunit-related protein) reactive 
CD8+ T-cells and induced a reduction in MHC-I and CD86 expression, HAMSB 
increased the Treg cell population. Splenic T-cells from NOD mice that were orally 
treated with HAMSB, when transferred into immunodeficient NOD-SCID mice, reduced 
T1D severity in receptor NOD-SCID mice. Fecal transplant of gut microbiota from NOD 
mice fed the HAMSA/HAMSB diet into GF NOD mice transferred diabetes protection. 
(b) NOD mice that express a transgene encoding the αβ TCR derived from a CD8+ T-cell 
clone specific against IGRP (NOD8.3) undergo acute T1D. The HAMSA diet inhibits the 
specific proliferation of IGRP reactive CD8+ T-cells NOD8.3 and, ultimately, T1D 
progression. In an effort to provide both a mechanistic explanation and to increase the 
potential clinical relevance of their findings, Mariño et al. fed NOD mice with special 
diets designed to release large amounts of specific SCFAs after bacterial fermentation. As 
expected, mice fed acetylated high-amylose maize starch (HAMSA) showed higher 
concentrations of acetate, whereas mice fed butyrylated high-amylose maize starch 
(HAMSB) presented higher concentrations of butyrate. Notably, both diets induced local 
and systemic increases in the corresponding SCFA levels, but had no effect on body 
weight or food or energy intake. Confirming their hypothesis that bacterial metabolites 
can protect genetically prone animals from developing T1D, animals fed either HAMSA 
or HAMSB presented a significantly reduced incidence of diabetes. Mice fed a 
combination of these diets demonstrated an even higher protection against diabetes, 
suggesting different mechanisms of action for acetate and butyrate. This finding was 
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further confirmed in experiments using NOD8.3 mice, which express a transgene 
encoding the αβ T-cell antigen receptor derived from a CD8+ T-cell clone specific against 
islet-specific antigen glucose-6-phospatase catalytic subunit-related protein (IGRP), 
which is a major target of autoreactive T-cells in pancreatic β-cells [36]. Even in this 
model of aggressive and rapidly progressing disease, a diet designed to release large 
levels of acetate showed a protective effect, as evidenced by both a delay in diabetes 
progression and a diminished percentage of IGRP-specific CD8+ T-cells (Figure 1-2).
 The authors also found a remarkable reduction in the number of B cells from the 
spleen and Peyer’s patches from NOD mice that were fed the HAMSA diet. Moreover, 
B-cells from spleen from animals fed the HAMSA diet also expressed lower levels of 
major histocompatibility complex class-I (MHC-I) and costimulatory CD86 molecules. 
These results strongly indicate that impaired antigen presentation likely causes a 
reduction in autoreactive CD8+ T-cells and concomitant protection against diabetes. 
These results fully agree with the previous report from the same group showing that 
cross-presentation by antigen presenting B-cells of islet-derived autoantigens drives the 
expansion and differentiation of self-reactive CD8+ T-cells in the pancreatic lymph node 
into effector cells, a critical process for the transition from clinically silent insulinitis to 
overt diabetes [37]. 
 Butyrate has been linked to an increase in the number and activation status of Treg 
cells [38]. Because Tregs cells are known to play a critical role in controlling T1D [39],
 the 
authors next tested the hypothesis that HAMSB-fed animals would have increased 
numbers of Treg cells and would thus prevent autoreactive T-cells from inducing T1D. In 
an elegant reverse protection approach, spleen T-cells from NOD mice fed with the 
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different diets were transferred into severe combined immunodeficiency mice (NOD-
SCID). Because SCID mice are depleted of B- and T-cells, the experiment allowed the 
authors to study the direct effects of the individual diets on the donor T-cells. In this 
rapidly progressing T1D model, the authors found that the adoptive transfer of spleen T-
cells derived from animals fed the HAMSB (but not HAMSA) diet almost completely 
protected host animals from diabetes development. Surprisingly, spleen T-cells obtained 
from animals fed with the original high-amylose resistant starch (HAMS) were also 
protective, albeit to a lesser extent. Further analysis showed that HAMSB-fed animals 
promoted the conversion of CD4+ T-cells into Foxp3+ IL-10-producing (Treg) cells. 
Although this result supports a putative role of Treg cells in butyrate-mediated protection 
against diabetes, a formal demonstration that such Treg cells are indeed responsible for 
ablating diabetes by inhibiting autoreactive T-cell proliferation was not provided (Figure 
1-2). 
 Finally, the authors analyzed changes in the gut microbiota of animals fed with 
the specialized diets. As expected, NOD mice fed the HAMSA and, to a lesser extent, the 
HAMSB diets presented a higher percentage of Bacteroides—a genus that has been 
linked with diabetes protection [34]. Importantly, fecal transplant of gut microbiota from 
NOD mice fed with the acetate-rich HAMSA diet into GF NOD mice was sufficient to 
elevate levels of acetate and transfer diabetes protection, thus further highlighting the 
relevance of gut microbiota in T1D pathogenesis (Figure 1-2). However, from a 
translational point of view, fecal transplants are associated with technical challenges and 
an almost overwhelming physiological stress and social stigma [40]. Thus, future 
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experiments should address whether individual bacterial species isolated from colonized 
GF could also transfer diabetes protection. 
 Collectively, the data presented by Mariño et al. [30] highlight that acetate and 
butyrate, which are two of the main products of bacterial fermentation, can provide 
disease protection in a mouse model of autoimmune diabetes. Because each metabolite 
acts through different molecular mechanisms (acetate reduces the proliferation of 
autoreactive T-cells by minimizing B cell antigen presentation to T-cells, whereas 
butyrate increases the number and activity of Treg cells), their additive effects could be 
beneficial for controlling other immune-based disorders, particularly those of 
gastrointestinal origin (for example, chronic inflammatory bowel diseases such as 
Crohn’s disease or colitis ulcerosa). Investigations in this regard are warranted and are 
largely fueled by the increasingly accepted role of the gut microbiota in the development 
and control of several metabolic diseases, as well as the growing interest in the potential 
use of prebiotics and probiotics as therapeutic tools to improve gut integrity [41]. The 
sheer complexity and inter-personal variation of the gut microbiota make any attempt to 
manipulate it extremely challenging. However, this study opens the door for the use of 
medicinal food (nutraceuticals) that is rich in bacterial metabolites as a promising and 
cost- effective treatment against T1D and other autoimmune diseases. 
1.1.4 Association between gut microbiota and metabolic health 
The gut microbiota of lean and obese individuals was first compared in a seminal 
study by Ley, et al. in 2006 [42] using 16S rRNA sequencing (the 16S rRNA gene is a 
section of prokaryotic DNA found in all bacteria that codifies for the small subunit of the 
ribosome and sequencing of its hypervariable regions allows us to identify bacterial 
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species at various taxa levels). Sequencing of DNA extracted from fecal samples 
demonstrated that obese individuals present a higher level of Firmicutes and lower level 
of Bacteroidetes than lean individuals [42], which validated previous murine studies [43]. 
Subsequent studies revealed that the gut microbiota composition of obese individuals is 
less diverse than in lean individuals [44, 45]. However, different results have also been 
reported [46, 47], and debate continues regarding the significance of the Firmicutes and 
Bacteroidetes proportion. Recent meta-analysis study has shown that the microbial 
changes associated with obesity are not based on phylum differences, but rather are the 
consequence of numerous small differences within the bacterial community [48]. 
Therefore, it is important to understand the overall composition of the gut microbiota 
rather than simply the proportion of Bacteroidetes to Firmicutes. Importantly, not only 
different bacteria, but also the metabolites they produce (postbiotics) can play a role in 
obesity and metabolic syndrome [49]. For example, patients with type-2 diabetes have 
reduced levels of SCFA-producing bacteria [50, 51], and some SCFAs (e.g., butyrate) 
facilitate enhanced insulin sensitivity and fatty-acid oxidation in muscle as well as 
increased satiety [52, 53]. Because obesity has been linked to less diverse gut microbiota 
composition than in lean individuals, it may be important to increase its diversity, and 
nutritional approaches to do so (via combined probiotic with prebiotic consumption) can 
promote weight loss. 
According to Brown, et al. there is a relationship between the gut microbiota and 
diseases such as obesity and type 2 diabetes, which are mainly influenced by diet taken 
[54]. They indicated that since gut microbiota participates in the body’s metabolism, 
energy balances and metabolism of glucose are influenced. Obesity is linked with 
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dysbiosis (a microbial imbalance) in the intestinal of human beings, therefore there is a 
high propensity that diet influences dysbiosis and host metabolism [55, 56]. Therefore, 
gut microbiota has vital roles in host metabolism as well as directing immune system [57, 
58]. Other studies have linked gut microbiota with type 2 diabetes since it has been 
asserted to resist insulin [59]. Therefore, gut microbiota has the propensity of influencing 
type 2 diabetes in collaboration with or obesity. 
1.1.5 Current strategies to modulate the gut microbiota to treat obesity and 
metabolic disorders 
Lifestyle modifications are an important part of obesity prevention and 
management. Unfortunately, too often they fail to consistently lead to appreciable weight 
loss [60]. Other alternatives such as pharmacotherapy and surgery can be indicated for 
short term weight management in severely obese patients, but significant risks and high 
price prevent them from being the treatment of choice for a majority of patients. 
Encouraged by its efficacy to treat Clostridium difficile infections [61], fecal gut 
microbiome transplantation (GMT) has been proposed as an alternative for patients that 
fail to manage weight under other treatments [62]. However, the use for GMT as a 
treatment for metabolic diseases is only experimental and security concerns as well as 
psychological stress makes it unappealing [63]. Therefore, it is clear that new approaches 
are needed to complement existing ones. 
Erejuwa, et al. indicate that gut microbiota have numerous roles that comprise of 
digestion, metabolism, and the prevention of pathogens [64]. The authors indicate that 
there have been a rise in prevalence of metabolic disorders such as obesity, and type 2 
diabetes. Therefore, in recent times there has been numerous studies that have linked gut 
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microbiota with some pathophysiological and the role that gut microbiota plays in 
metabolic disorders [65, 66].  Since there is a close association of gut microbiota and the 
metabolic disorders such as obesity, there have been numerous ways that have been 
suggested to modulate gut microbiota so as to manage the metabolic diseases. Some of 
the modulation suggested comprise of probiotics and probiotics [64, 67]. For instance, 
some scientific study on mice found that administering prebiotic supplements in obese 
mice have the propensity of improving the tolerance of glucose and the content of muscle 
content [68]. 
1.1.6 The role of probiotics and prebiotics in health enhancement 
Other studies have suggested that probiotics and prebiotics can be used to enhance 
health of individuals and mitigate chronic diseases such as diabetes type 2 and obesity 
[49, 69]. Prebiotics and probiotics are diet-based processes that can be used to health of 
the host by enhancing the composition of colonic microbiota. For instance, prebiotic and 
probiotic have been found to vary the overall composition of the gut microbiota if the 
dietary intervention are carried out. Some studies have indicated that prebiotics are 
dietary substrates that can enhance proliferation or activity of the bacteria that are present 
in the original colon. Prebiotic in the recent times have been defined as “selectively 
fermented ingredients that result in specific changes, in the composition and/or activity in 
the gastrointestinal (GI) microbiota, thus conferring benefit(s) upon host health” [70]. 
Numerous studies have validated the concept of prebiotic and the role that prebiotics play 
in minimizing the risk of bowel obstruction and other systematic diseases [71, 72]. 
Specifically, it was found that prebiotics have a strong potential of protecting human 
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beings from various chronic diseases or conditions such as type 2 diabetes and obesity 
[72, 73]. 
1.1.7 The role of diet in gut microbiota and health outcomes 
A wide body of research has been explored to investigate the role of diet on gut 
microbiota and the resulting health outcomes especially type 2 diabetes and obesity 
among with the health complications linked to these diseases. Conlon & Bird (2014) 
investigated the impact of diet and lifestyle on gut microbiota as well as the human health 
in a study that recognizes that diet is an important factor in regulating the composition 
and metabolic activity of gut microbiota [69]. Gut microbes are known to produce 
numerous number of bioactive compounds that can impact the health of an individual, 
therefore dietary means such as the consumption of fibers can be very vital in 
maintenance of a healthy gut microbiota population [69, 74]. Gut microbial have the 
capability of producing numerous products, and some of the products produced have 
adverse effect on the health of human beings [75]. The impact of diet in the gut 
microbiota and health has been vastly studied, for instance diets rich in fiber have been 
found to promote and maintain bowel health due to the fact that they increase digested 
mass [69]. Additionally, dietary fat have been found to influence the structure as well as 
the metabolic activity of gut microbiota, and this phenomenon has been associated with 
obesity [69, 76]. Studies indicate that high fat diets triggers circulation levels of bacteria 
that are associated with lipopolysaccharide (LPS), and this is can be attributed to an 
enhancement of intestinal permeability [77]. 
Graf, et al. (2015) indicated how important the human gut microbiota is, and the 
manner in which it is influenced by various factors such as diet [78].  The authors 
High-Fat/high-sugar 
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Antibiotic abuse 
 
 
 
↑ Systemic inflammation 
↑ Insulin resistance 
↑ Diabetes 
↑ Obesity 
↑ TH 17 cells 
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indicated that nutrients that are indigestible for human enzymes such as fiber provides 
substrates for the intestinal microbial metabolism. The fact that bacteria are responsible 
for triggering the fermentation of different substrates, complex diet can either promote or 
inhibit growth for some phylotypes [79]. For instance whole grain products are mainly 
characterized with high content of fiber, and the fact that the human body doesn’t have 
any enzymes that can digest their structures they reach the colon where they are 
metabolized by the microbiota, which in turn inhibit the growth of different bacterial 
groups [80, 81]. The composition of the human gut microbiota can be argued to be stable 
and any short term dietary intervention does not seem to change the composition of the 
microbiota. Nonetheless, the microbial gene expression and consequently the functional 
profiles seems to adopt to changes in diet more easily [80, 82]. 
Heinritz, et al. (2016) conducted a research to ascertain the impact of high-fat or 
high fiber on intestinal metabolic markers where they used pigs in their study [83]. The 
main reason why the pigs were used is because they have the same dietary changes 
similar with those of humans. The study ascertained that there was a hypotrophic effect 
on the high-fat (HF) diet compared to low-fat (LF) diet. Diets rich in fiber have also been 
reported to be trophic to their ability to ferment easily, thereby enhancing production of 
SCFA that stimulates epithelial cell proliferation [83, 84]. Metabolic activity of gut 
microbiota is mainly influenced by the production of different microbial metabolites, for 
instance consumption of LF diet have the propensity of increasing the concentration of 
butyrate and acetate in cecum and colon [83, 85]. Therefore, the role of diet in regard to 
the composition and the metabolic activity of gut microbiota is very important since it has 
the propensity of influencing health [69]. Diet is a vital aspect that shapes gut microbiota, 
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and this means that diet and nutritional components should be taken into consideration 
since they can trigger diseases such as obesity [83]. For instance, some studies have 
indicated that harmful and pathogenic gut microbes are linked to diseases such as obesity, 
and this is because some diet causes imbalances of gut microbiota [56, 79]. Thus, 
different nutrients have different components that impacts gut microbiota, which in turn 
influences aspects such as the metabolic activity. 
According to previous research on the impact of diet on health-type 2 diabetes 
and obesity, it is worth to note that the adverse metabolic effects of ‘western’ style of diet 
characterized by high sugar and salt levels as well as highly processed foods go beyond 
the macronutrients [86]. For instance, artificial sweeteners and emulsifiers have been 
linked to the development of metabolic syndrome aspects through the modulation of the 
microbiota mice [87, 88]. According to the findings from a study conducted by McGill, et 
al. there was evidence of insulin resistance when hosts fed on high doses of artificial 
sweeteners after only 7 days of intake of the sweetener [89]. These findings provide 
insights into the conclusion that there is scientific evidence to suggest that artificial food 
additives, especially those with high sugar level contribute immensely to development of 
metabolic disease by disturbing the microbiota. This gives rise to the development of 
diseases such as type 2 diabetes and obesity. Worth noting is the insights provided by the 
analysis of the differences in susceptibility of the western countries and those in 
developing countries especially in Africa. For instance, western dietary trends are 
historically characterized by low levels of dietary fiber based on plants, which is an 
essential fuel for microbiota [90, 91]. As such, the inclusion of abundant level of 
nutrients that negatively impact the microbiota in the absence of dietary fiber creates a 
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situation that makes it easy to understand metabolic diseases as such dietary consumption 
is the leading causes of diabetes and obesity. 
1.1.8 The role of gut microbiota in the regulation of fat storage and homeostasis 
 Research shows evidence of the influence of diet in the gut microbiota and health 
especially diabetes and obesity. These two health complications are evidenced by the role 
of the gut microbiota in the regulation of fat storage and homeostasis [12, 92]. According 
to a study conducted by Chassaing, et al., (2015), it is reported that gut barrier 
dysfunction and microbiota alteration are resultant are induced by two dietary 
emulsifiers; polysorbate-80 and carboxymethylcellulose in mice [93]. As a result, the 
mice experienced major metabolic disorders, low-grade inflammation, weight gain and 
rise in blood sugar level. While it is not conclusive that intake of ‘western’ processed 
foods in uniquely responsible for the increase in cases of inflammatory diseases and 
obesity, there is no doubt that consumption of several of such compounds could play a 
major role in inducing worse metabolic health and low-grade inflammation in organisms 
that may be susceptible to metabolic disease. A large body of literature relate to the 
comprehension of the role of gut microbiota in influencing metabolism, absorption and 
storage of calories after digestion [94, 95]. Research suggests that gut microbes alter the 
manner in which the human body reacts to elements of diet and nutrition to influence 
metabolism. However, there is lack of conclusive evidence on the mechanisms that 
underlie this process as they are highly complex to reconcile. Nevertheless, emerging 
trends in the field suggests that obesity is linked to reduced diversity of the gut 
microbiota [96, 97]. 
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1.1.9 Gut microbiota and sources of dietary fats 
 Most of the experiment that evaluate the role of diet in the gut microbiota and 
type 2 diabetes, obesity use western type of diet, which is full of processed foods and 
devoid of fibers [98]. Such foods are filled with calories from the saturation of sucrose 
and fat, and they illustrate that gut microbiota significantly regulates the occurrence of 
obesity through additional pathways [99, 100]. For instance, research shows that germ-
free mice that have been fed with a diet that is low in sucrose and high in fiber show 
partial protection from obesity, primarily microbiota-dependent obesity [101]. This type 
of protection is withdrawn upon the omission of sucrose from the diet. For purposes of 
this analysis, it is very important that the source of the dietary fats be understood. This is 
because the two types of dietary fats; saturated and unsaturated deliver diverse influence 
on the gut microbiota [102, 103]. Moreover, the modified microbiota caused by intake of 
unsaturated fats plays a role in protecting human beings from weight gain resulting from 
such feeding [76, 104]. Subsequently, weight gain becomes inevitable with consumption 
of unsaturated fats than when saturated fats are consumed. The review of previous 
findings suggest that fats and simple carbohydrates could result in unexpected impacts on 
the metabolism of users of such diet through microbiota. 
1.1.10 Link between gut microbiota, insulin resistance, obesity, and inflammatory 
reactions 
 Insulin resistance and obesity have been linked to the rise in the rate of infiltration 
of inflammation and macrophages in the adipose tissue [105, 106]. As gut microbiota is 
reported to be a significant contributor of increasing the prevalence of the obese 
phenotype, mostly in mice as it has been confirmed by several researchers, it is also 
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deemed to contribute to a high level of adipose inflammation [107, 108]. This type of 
model where adipose inflammation is independent of diet but dependent on microbiota 
can be evidenced by the finding resulting from a study conducted using C57Bl6 common 
laboratory mice. The study reported that the mice exhibited minimized adiposity as well 
as lower levels of endotoxins in the blood when fed with diets that have been inducted 
with adiposity. Moreover, the mice demonstrate enhanced level of glucose metabolism 
and a reduced level of macrophage infiltration in the white adipose tissue. The occurrence 
of obesity in mice is also reported to be linked to the increase in the amount of mast cells, 
T cells as well as the reduction in the amount of regulatory T cells [38, 109]. When using 
the mouse models, there is an indication of generation of short-chain acids and 
fermentation of fiber, which demonstrates the promotion of anti-inflammatory reactions 
both through regulatory T cells systematically and within the gut [35, 110]. While 
interleukin (IL)-17 (an inflammatory cytokine) is involved in the pathogenesis of diabetes 
and obesity [111, 112]. There is no doubt that the dietary fiber and the short-chain acids 
produced in the model mice result in a positive metabolic effect through non-
immunological strategies [113]. The mouse used for the study are those that had been 
obesity-induced.  However, it is not clear whether the same outcome that would result 
from the immune system could lead to metabolic alterations. While the processes that 
underlie these procedures remain unclear, research suggests that when high fat diets are 
supplements with fermented fiber, the mice are protected from suffering from obesity and 
its associated diseases and disorders. 
 It is widely acknowledged that diet, especially fiber and processed foods have a 
great influence on gut microbiota and consequently on type 2 diabetes and obesity. As 
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obesity is significantly correlated to the development of low grade chronic inflammation, 
diabetes and obesity are common resultant health complications due to the contribution of 
the inflammation on the risk of insulin resistance and body weight. Moreover, individuals 
risk suffering from other health problem related to obesity including cardiovascular 
diseases [105]. Obesity is also attributed to modified gut microbiota. This is illustrated by 
the metabolism of indigestible polysaccharides in a process that produces 
monosaccharides and short chain acids that allow for such products to be absorbed and 
stored in the body as fat. The general body of research tying diet to gut microbiota and 
health outcomes demonstrates that diet low in fiber interacts to effect alternation of the 
inflammation in the intestines, a move that is followed by other health complications such 
as insulin resistance, adiposity, and weight gain, hence predisposing individuals to type 2 
diabetes and obesity. 
1.1.11 Dairy products for probiotic benefits 
 Manipulation of the gut microbiota through dietary intervention and probiotic 
supplements is a promising strategy for the prevention and treatment of metabolic 
diseases. As a consequence, worldwide sales of probiotics have more than doubled in the 
last decade alone [114]. On the other hand, probiotic bacteria have often been assessed as 
dietary supplements or in dairy products, such as yogurt or kefir [115, 116]. Because of 
its nutritional values and longer shelf life, fermented cheese might be an ideal vector for 
the delivery of probiotics. Cheese is a good matrix for transferring probiotic bacteria into 
the gastrointestinal tract, due to the buffering capacity of the milk proteins which will 
protect the cells during transit; this is mainly due to their higher fat content and denser 
structure that may protect the bacteria against the acidic environment of the 
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gastrointestinal tract [117-119]. While several studies have shown an inverse association 
between dairy products and metabolic syndrome [120-122], however, it is not clear 
whether the same outcome that would result from the different sources of (cow, goat and 
camel) and formats (milk, yogurt, probiotic yogurt, cheese and probiotic cheese) could 
lead to gut microbiota alterations. While the processes that underlie these procedures 
remain unclear, research suggests that when full-fat dairy are supplements with specified 
probiotic, the mice are protected from suffering from obesity and its associated diseases 
and disorders. 
1.1.12 Links between diet, antibiotics treatment, gut microbiota, and immunological 
status 
 Linking diet to the structure and dynamic operation of microbial communities 
and, more importantly, to the immunological status of the host has proven elusive 
because of numerous uncontrolled genetic and environmental variables and the 
intrinsically complicated nature of clinical trials. In the past, germ-free mice (animals 
born and raise without any exposure to micro-organisms) have provide an excellent 
system for controlling host genotype, diet and environmental conditions. In addition, they 
can be colonized at specific life stages with different microbial communities and thus 
perform comparative metagenomic studies of donor communities [123, 124]. However, 
raising and maintaining a germ-free mice colony is challenging. Hence, a broad range 
antibiotic treatment of mice is considered a viable alternative and has been successfully 
used in the past. Antibiotics have been administered by either oral or intraperitoneal route 
[125-127]. However, several studies have shown a negative repercussions between 
antibiotic treatment and composition of gut microbiota, including dysbiosis as well as 
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metabolic functions and immune responses [128, 129]. While the processes that underlie 
these procedures remain unclear, research suggests that when diet are supplements with 
specified probiotic and prebiotic, the mice are protected from suffering from this 
repercussions as well as attenuating antibiotic-induced disturbances in the gut microbiota 
composition. 
1.1.13 Summary 
 This review explores a wide scope of literature on the effects of diet on gut 
microbiota and health outcomes including obesity and metabolic disorders taking into 
perspective diets such as high fat, whole grains, dairy products, prebiotic and probiotic. 
High fiber diet as well as diet rich in prebiotic and probiotic is deemed to be effective in 
mitigating the occurrence of diabetes and obesity as they enhance metabolism and 
digestion, minimizing the risk of bowel obstruction. Recent human and animal studies 
suggest that such intervention can promote health benefits by influencing the aspects of 
metabolism and immunity. However, study of the multi-role association between the diet, 
host and the microbiota remains to be clarified. My dissertation attempts to clarify the 
problem of how gut microbiota (taxonomic composition and predicted functional 
capacities) affects obesity and metabolic disorders, and provided important information 
on correcting disruption of the gut microbiota resulting from obesity or imbalanced diets 
using a combine probiotic and prebiotic (synbiotics), and dairy products which can be 
effectively employed for the delivery of probiotics to the gut as well as for the support of 
growth and survival of probiotic bacteria. 
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 Abstract: Targeting gut microbiota with synbiotics (probiotic supplements 
containing prebiotic components) is emerging as a promising intervention in the 
comprehensive nutritional approach to reducing obesity. Weight loss resulting from low-
carbohydrate, high-protein diets can be significant, but has also been linked to potentially 
negative health effects due to increased bacterial fermentation of undigested protein 
within the colon and subsequent changes in gut microbiota composition. Correcting 
obesity-induced disruption of gut microbiota with synbiotics can be more effective than 
supplementation with probiotics alone because prebiotic components of synbiotics 
support growth and survival of probiotic bacteria. The purpose of this placebo-controlled 
intervention clinical trial was to evaluate effects of a synbiotic supplement on 
composition, richness and diversity of gut microbiota and associations of microbial 
species with body composition parameters and biomarkers of obesity in human subjects 
participating in a weight loss program. The probiotic component of the synbiotic used in 
the study contained Lactobacillus acidophilus, Bifidobacterium lactis, B. longum, and B. 
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bifidum and the prebiotic component was a galactooligosaccharide mixture. The results 
obtained indicated that there were no statistically significant differences in body 
composition (body mass, BMI, body fat mass, body fat percentage, body lean mass, and 
bone mineral content) between the placebo and synbiotic groups at the end of the clinical 
trial (3-month intervention, 20 human subjects participating in weight loss intervention 
based on a low-carbohydrate, high-protein, reduced energy diet). Synbiotic 
supplementation increased abundance of gut bacteria associated with positive health 
effects, especially Bifidobacterium and Lactobacillus, and it also appeared to increase the 
gut microbiota richness. A decreasing trend in the gut microbiota diversity in the placebo 
and synbiotic groups was observed at the end of trial, which may imply the effect of the 
high-protein, low-carbohydrate diet used in the weight loss program. Regression analysis 
performed to correlate abundance of species containing in the synbiotic supplement with 
body composition parameters and biomarkers of obesity found association between a 
decrease over time in blood glucose and an increase in Lactobacillus abundance, 
particularly in the synbiotic group. However, the decrease over time in body mass, BMI, 
waist circumstance, and body fat mass was associated with a decrease in Bifidobacterium 
abundance. The results obtained support the conclusion that synbiotic supplement used in 
this clinical trial modulates human gut microbiota by increasing abundance of potentially 
beneficial microbial species and that the supplement may have positive effects on 
metabolic parameters in obesity. 
 
Keywords: synbiotic; prebiotic; probiotic; gut microbiota; obesity; weight loss; body 
composition; obesity biomarkers 
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2.1. Introduction 
The gut microbiota appears to play a role in the pathogenesis of obesity and 
obesity-associated diseases [130, 131]. This community can contribute to the 
development of obesity primarily by influencing dietary energy intake and intestinal 
absorption of nutrients [132, 133], but it can also provide the human host with benefits 
besides energy extraction, including a reduction of low grade chronic inflammation 
associated with obesity and metabolic syndrome [134, 135]. Therefore, gut microbiota 
may be considered as a promising target in the comprehensive dietary approach to the 
prevention and treatment of obesity, including weight loss and weight maintenance [136, 
137]. 
It is important to note that high-protein and low-carbohydrate diets, which are 
often successfully used for weight loss, have been associated with a decrease in bacteria 
considered beneficial to health [47, 138, 139]. Those diets have also been found to induce 
protein fermentation by gut microbiota with formation of metabolic byproducts [140-
142], which can trigger inflammation in the colon [143]. Furthermore, high levels of 
protein fermentation by gut bacteria have been associated with increased genotoxicity 
[144]. Thus, a healthy, diverse, and less toxic gut microbiota is critical for wellbeing of 
the host [145, 146]. 
Dietary intervention with probiotics, prebiotics or synbiotics (which combine 
probiotic and prebiotic components) aimed at correcting disruption of the gut microbiota 
resulting from obesity or imbalanced diets may provide health benefits by facilitating 
weight loss and maintenance [147, 148]. Recent human and animal studies suggest that 
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probiotics can promote weight loss in obesity [149, 150], but studies on the role of 
synbiotics in obesity are very limited [151, 152] and further studies are warranted [151]. 
The objective of this placebo-controlled intervention clinical trial was to evaluate 
effects of a synbiotic supplement containing Bifidobacterium and Lactobacillus strains on 
the human gut microbiota in relation to changes in body composition and metabolic 
biomarkers in obesity. The results obtained and bioinformatic analysis support the 
conclusion that the synbiotic supplement used in this study modulates the human gut 
microbiota by increasing abundance of beneficial microbial genera and that the 
supplement may also have beneficial effects on metabolic parameters in obesity. 
 
2.2. Materials and Methods 
2.2.1. Study Participants, Clinical Trial Design and Prebiotic Supplement 
Participants of the study were enrolled in the weight loss program (Profile by 
Sanford Health, Sioux Falls, SD). Twenty new weight loss participants, male and female, 
were recruited for the study and randomly assigned to the placebo (control) or synbiotic 
(treatment) group. Those enrolled were initially overweight/obese and had a mean BMI 
of 33.5 kg/m2. Placebo group (n=10) followed the weight loss program eating plan (a 
low-carbohydrate, high-protein dietary pattern with reduced energy (4,000-5,000 kJ/d) 
intake). The synbiotic group (n=10) was on the same diet plan, but additionally received a 
synbiotic (probiotic plus prebiotic) supplement daily for 3 months. The control group 
received the placebo supplement similar in appearance and of the same energy content as 
the synbiotic supplement. Human subjects with conditions that may impact gut 
microbiota (gastrointestinal, autoimmune, and metabolic diseases and medications, 
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particularly antibiotics) were not included in the trial. All subjects gave their informed 
consent for participating in the study. The study was approved by the SDSU Institutional 
Research Board (Approval number: IRB-1604005). The clinical trial has been registered 
in the ClinicalTrials.gov (NCT number: 03123510). 
The probiotic component of the synbiotic used in the study contained a blend (one 
capsule contained 69 mg or 15x109 CFU) of proprietary strains of Lactobacillus 
acidophilus DDS-1, Bifidobacterium lactis UABla-12, B. longum UABl-14, and B. 
bifidum UABb-10. The probiotic supplement was produced by UAS Labs (Wausau, WI). 
The prebiotic component was a trans-galactooligosaccharide (GOS) mixture at a dose of 
5.5 g/d (2.75 g GOS and the remainder simple sugars) produced by Clasado BioSciences 
Ltd. (St. Helier, Jersey, UK) [153]. 
2.2.2. Body Composition and Metabolic Parameters 
Body mass index (BMI) was calculated using body weight and height measured 
with bare feet and in minimal clothing using a stadiometer and an electronic scale. Body 
composition parameters (body fat mass and percentage, body lean mass, and bone 
mineral content) were acquired before and after 3 months of synbiotic intervention by 
dual-energy X-ray absorptiometry (DXA) using a whole-body scanner (Hologic APEX, 
Bedford, MA)[154]. Whole-body images were obtained and analyzed by a technologist 
certified as a Certified Bone Densitometry Technologist by the International Society of 
Clinical Densitometry. Phantom scans were performed before participant testing as an 
independent assessment of system calibration, and quality control data were plotted and 
reviewed periodically. The A1CNow+ test (MDSS GmbH, Germany/Polymer 
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Technology Systems, Inc., USA) was used for quantitative measurement of the percent of 
glycated hemoglobin (%A1C) in the capillary blood (fingerstick) samples. 
2.2.3. Microbial DNA Extraction and the 16S rRNA Gene Sequencing  
Fecal samples from the participants were obtained before and after the synbiotic 
or placebo intervention with no more than 24 h prior to the study visit. Samples were 
collected using the OMNIgene-GUT stool/feces collection kit (OMR-200, DNA Genotek, 
Ottawa, Canada). Forty fecal specimens from unique participants were sent to DNA 
Genotek for the microbiome analysis. DNA was extracted and quantified and library 
preparation was performed with Illumina’s NexteraXT protocol. Aliquots of each sample 
were extracted using PowerMag microbial DNA isolation kit (MO BIO Laboratories, 
Carslbad, CA) optimized for the KingFisher Flex automated extraction platform 
(ThermoFisher, Pittsburgh, PA). A bead-beating step with glass beads was used to 
maximize recovery of DNA from low-abundance and difficult to lyse microorganisms. 
The concentration of extracted DNA was measured using Qubit Fluorometer (Invitrogen, 
Carslbad, CA), and the sample purity was confirmed spectrophotometrically by 
measuring the A260/A280 ratio.  
For DNA sequencing, Illumina sequencing adapters and dual-index barcodes 
(Nextera XT indices) were added to the amplicon target via polymerase chain reaction 
(PCR) amplification. 16S sequencing (2x300 bp PE V3-V4) was performed on Illumina’s 
MiSeq platform. Amplicon sequencing was performed to a target depth of 30,000 reads 
per sample. Paired-end reads from each sample were merged, screened for length and 
filtered for quality using DNA Genotek’s proprietary 16S pre-processing workflow. Read 
merging and quality filtering was performed on the raw sequencing reads to eliminate 
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any sequencing artifacts and low quality reads. Complete quality metrics including 
library quantification and sequencing run quality control are presented in Supplemental 
Materials (Figure 2-S1 and Table 2-S1). 
 
Figure 2-S1. Sequence counts per sample for raw, filtered and classified sequences 
ordered by increasing classified sequence counts. Dashed gold line indicates the 25,000 
sequence threshold used for rarefaction. A and B before sample numbers indicate the 
synbiotic and placebo groups, respectively. 
 
Metric Minimum Requirement Results 
% ≥ Q30 ≥ 75% 82.38 % 
Cluster Density ≥ 800 k/mm2 1,111 ± 19 k/mm2 
Clusters Passing Filter (%) ≥ 85% 86.49 ± 1.34 % 
Sequencing Yield ≥ 13.2 Gbp 14.04 Gbp 
PhiX Alignment (%) 12% - 18% 11.63 % 
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Table 2-S1. Sequence quality metrics per sequencing run. % ≥ Q30: The proportion of 
base calls that have a confidence score of 30 or more. This is a commonly cited metric 
that can be used to evaluate the overall quality of a sequencing run. Cluster Density: How 
efficiently the sequencer is able to bind sequences of DNA to the flow cell. A higher 
density represents a more efficient sequencing run. Clusters Passing Filter: The 
proportion of clusters that meet the sequencer’s minimum quality threshold for sequence 
quality. Only clusters that pass filter are included in the sequencer’s FASTQ output. 
Sequencing Yield: Refers to how many nucleotide base pairs were called by the 
sequencer. 1 Gbp (giga base pair) means the sequencer generated 1 billion base pairs of 
output. PhiX Alignment: PhiX is a sequencing library that is used as a positive control on 
each sequencing run. The sequencer aligns reads to the PhiX library to calculate 
sequence-based quality control metrics. We require that the percentage of reads that align 
to the PhiX library is within 20% of the spike-in amount of PhiX. 
 
2.2.4. Taxonomic Classification and Bioinformatics Analysis 
A curated reference taxonomic database was used to assign a taxonomic 
classification to the sequencing reads. High quality sequences were aligned to the curated 
reference database at 97% similarity using the NINJA-OPS algorithm, version 1.5.1 
[155]. At 97% sequence identity, each operational taxonomic unit (OTU) represents a 
genetically unique group of biological organisms. These OTUs were then assigned a 
curated taxonomic label based on the SILVA taxonomic database, version 123 [156]. The 
relative abundance of all taxa at the phylum and genus levels were plotted to visualize 
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sample-specific classifications. All samples were rarefied to an even depth of 25,000 
classified sequences per sample or more to eliminate effects of variance in sequencing 
depth. Samples with more than 25,000 classified sequences per sample were included in 
the rarefied OTU table and downstream analyses, thus allowing to rarefy the samples to 
52,150 read pairs/sample, as this was the read count of the sample with the fewest reads 
(see Table 2-S1).  
Alpha diversity metrics (observed OTUs, Shannon index, and Chao1 diversity) 
were calculated on the rarefied OTU table using the alpha_rarefaction.py workflow in 
QIIME 1.9.1 [157]. Beta diversity metrics (weighted and unweighted UniFrac distances) 
were calculated on the rarefied OTU table with the beta_diversity.py workflow in QIIME 
1.9.1 and Bray-Curtis dissimilarity index was calculated on the species level 
summarization of the rarefied OTU table. Differences between groups were estimated 
using Permutational Multivariate Analysis of Variance (PerMANOVA; adonis function 
in the vegan R package). Principal Coordinates Analysis (PCoA) was applied to each beta 
diversity distance matrix using the dudi.pco function from the R package made4 (version 
1.48.0). The first two major axes were plotted (R package ggplot2 version 2.2.1), and the 
percentage of variance explained by each axis was indicated. 
2.2.5. Statistical analysis 
A one-way ANOVA with independent samples t-test was used for group 
comparison of the body composition and metabolic parameters (SPSS Statistics, v. 25). 
The results were expressed as mean ± SD, and mean differences were considered 
significant at p < 0.05. Significant differences in alpha diversity between groups were 
determined using estimated marginal means analysis applied to linear mixed model, 
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which was built with alpha diversity as the response variable, the treatment groups and 
time points as the predictor variables, and subject number as a random variable. 
Significant differences in beta diversity between groups were determined using 
PerMANOVA with beta diversity as the response variable and the treatment groups and 
time points as predictor variables. Statistical analyses of diversity metrics were performed 
using R version 3.3.2 (R Core Team, 2015). 
Associations between relative abundance of gut bacteria and the body 
composition and metabolic parameters were calculated using Pearson’s linear correlation 
coefficient. Regression analysis to correlate microbial abundance of species/genera 
present in the synbiotic supplement (Bifidobacterium and Lactobacillus) with body 
composition parameters and biomarkers of obesity was performed by applying ANOVA 
to a mixed linear model build with the percent abundance of microbe of interest as the 
response variable and the interaction between the specific parameter (gender, age, body 
mass, weight circumstance, BMI, body fat mass, body fat percentage, lean mass, bone 
mineral content, or HbA1C), treatment groups (placebo or synbiotic) and time points 
(beginning or end of trial) as predictor variables, with subject number as random variable. 
The Bonferroni correction method was used for multiple testing. Software versions used 
for the data analyses are provided in supplemental Table 2-S2. 
  
35 
 
 
Software Version 
Trimmomatic 0.36 
NINJA-OPS 1.5.1 
SILVA taxonomic database 123 
QIIME 1.9.1 
SPSS Statistics 25 
R 3.3.2 
R packages  
emmeans 1.2 
lme4 1.1-17 
Matrix 1.2-14 
scales 0.5.0 
ggplot2 2.2.1 
reshape2 1.4.3 
made4 1.48.0 
scatterplot3d 0.3-41 
gplots 3.0.1 
RColorBrewer 1.1-2 
ade4 1.7-11 
vegan 2.5-1 
lattice 0.20-35 
permute 0.9-4 
Table 2-S2. Software versions for data analysis. 
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2.3. Results 
In this placebo-controlled intervention clinical trial, effects of the synbiotic 
supplement on richness and diversity of gut microbiota and associations of microbial 
species with measurements of body composition and biomarkers of obesity were 
evaluated in human subjects participating in a weight loss program. Twenty participants 
were recruited in the study (10 in the placebo (control) group and 10 in the synbiotic 
(treatment) group). The average BMI of the study participants was 33.5 kg/m2 and the 
average age was 47.4 years. The majority of participants were female (80% in the 
placebo group and 70% in the synbiotic group). 
Participants were enrolled in the weight loss program at the beginning of the 
study and followed a low-carbohydrate, high-protein, reduced-energy intake eating plan. 
The probiotic component of the synbiotic used in the study contained Bifidobacterium 
spp. and Lactobacillus acidophilus strains, and the prebiotic component stimulating 
growth of these bacteria was a trans-galactooligosaccharide mixture.  Blood and fecal 
samples were collected and body composition and metabolic parameters measured at the 
beginning and end of the three-month intervention trial. Seven human subjects in the 
placebo group and eight human subjects in the synbiotic group had body composition 
parameters measured using DXA. No participants dropped out of the study during the 
intervention period. 
2.3.1. Body Composition and Metabolic Parameters 
The results obtained indicate that there were no statistically significant differences 
in the body composition parameters (body mass, waist circumstance, BMI, body fat mass, 
body fat percentage, body lean mass, bone mineral content (as measured by DXA) and 
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obesity-related biomarkers (blood glucose, as measured by HbA1C levels) between the 
placebo and synbiotic groups at the end of the clinical trial (three-month synbiotic 
intervention) (Table 2-1). Body mass, waist circumference, BMI, fat mass, fat 
percentage, and glucose level significantly decreased or demonstrated a decreasing trend 
in the placebo and synbiotic groups at the end of the trial (participants in both the placebo 
and synbiotic groups were enrolled in the weight loss program). The decrease in HbA1C 
percentage at the end of trial was statistically significant in the synbiotic group, but not in 
the placebo group. Individual body composition parameters, including the DXA scan 
measurements, are presented in appendix Table 2-S3. 
Characteristics/Parameters Placebo Synbiotic p 
Sex (%)    
Male  20.0 30.0  
Female  80.0 70.0  
Age (years) 47.0 ± 15.4 47.8 ± 8.99 0.88 
Height (cm) 171.8 ± 12.9 163.4 ± 9.63 0.30 
Body mass (kg)    
Baseline  97.6 ± 23.1 90.6 ± 11.9 0.40 
End of trial  90.0 ± 21.9 83.4 ± 11.4 0.41 
Body mass change (%) 7.78 ± 5.30* 7.94 ± 3.88* 0.86 
BMI (kg/m2)    
Baseline 32.77 ± 4.51 34.20 ± 5.60 0.53 
End of trial 30.14 ± 4.04 31.48 ± 5.23 0.53 
BMI change (%) 8.02 ± 1.65* 7.95 ± 1.52* 0.82 
WC (cm)    
Baseline  106.9 ± 12.47 109.6 ± 8.07 0.57 
End of trial 101.1 ± 12.89 102.6 ± 8.48 0.76 
WC change (%) 5.42 ± 5.78* 6.38 ± 4.16* 0.29 
Body Fat Mass (kg)    
Baseline 40.66 ± 6.92 36.97 ± 11.35 0.47 
End of trial 37.44 ± 6.99 34.06 ± 11.58 0.51 
Fat mass change (%) 7.91 ± 2.73* 7.87 ± 3.94* 0.37 
Body Fat (%)     
Baseline 40.97 ± 5.02 40.51 ± 8.96 0.90 
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End of trial 39.51 ± 4.53 39.13 ± 9.47 0.92 
Body fat change (%) 3.56 ± 1.49* 3.40 ± 2.97 0.20 
Body Lean Mass (kg)    
Baseline  57.39 ± 17.76 51.13 ± 8.87 0.39 
End of trial 55.61 ± 16.15 49.47 ± 8.64 0.36 
Lean mass change (%) 3.10 ± 2.10* 3.24 ± 1.14* 0.25 
BMC (kg)     
Baseline 2.66 ± 0.64 2.38 ± 0.48 0.34 
End of trial 2.68 ± 0.67 2.38 ± 0.48 0.32 
BMC change (%) 0.75 ± 0.05 0.16 ± 0.01 0.10 
Body Lean Mass + BMC(kg)    
Baseline 60.05 ± 18.38 53.52 ± 9.35 0.39 
End of trial 58.30 ± 16.78 51.86 ± 9.11 0.36 
Lean mass +BMC change (%) 2.91 ± 2.08* 3.10 ± 1.13* 0.26 
HbA1C (%)    
Baseline 5.36 ± 1.07 5.39 ± 0.28 0.93 
End of trial 5.06 ± 0.37 5.06 ± 0.43 1.00 
HbA1c change (%) 5.59 ± 0.89 6.12 ± 0.47* 0.24 
 
Table 2-1. Characteristics of study participants at the beginning and end of the 
intervention clinical trial.  BMI, Body Mass Index; WC, Waist Circumference; BMC, 
Bone Mineral Content; HbA1C, glycated hemoglobin. The duration of the trial was 3 
months. The study enrollment period was 6 months, and subjects were assigned to the 
groups in a chronological order. n = 10 for the placebo group and n = 10 for the synbiotic 
group (7 human subjects in the placebo group and 8 human subjects in the synbiotic 
group completed DXA scans). The results are expressed as mean ± SD. A one-way 
ANOVA with independent t-test was used for the group comparison (SPSS Statistics, v. 
25). (*), p < 0.05, as compared between the beginning (baseline) and end of trail for the 
same group (placebo or synbiotic); p value, as compared between the placebo and 
synbiotic groups. 
39 
 
The findings obtained demonstrate that the low-carbohydrate, high-protein, 
decreased-energy diet is effective for weight loss and normalizing obesity-related 
metabolic parameters (blood glucose), but they do not support the conclusion that the 
synbiotic supplement used in the study has significant impact on body mass and body 
composition of human subjects participating in this weight loss program. 
2.3.2. Gut Microbiota 
To characterize effects of the synbiotic supplement on gut microbiota of the study 
participants, fecal samples were obtained before and after the synbiotic intervention, gene 
sequence analysis was performed, and individual variations as well as group differences 
of gut microbiota were compared. All samples underwent taxonomic classification and 
were included in the complete OTU table (supplemental Table 2-S4), however, those 
with fewer than 25,000 classified sequences per sample were excluded from further 
analysis. Remaining samples were rarefied to a depth of 52,150 sequence reads per 
sample. Raw read counts per sample, quality of filtered read counts per sample, and 
sequence quality metrics per sequencing run are provided in Supplemental Materials (see 
Figure 2-S1 and Table 2-S1). The relative abundance of all taxa at the phylum, genus, 
and species levels were plotted to visualize broad taxonomic differences by treatment 
groups and time points with a percentage of each number in all sequencing reads (Figure 
2-1 and Figure 2-S2). In addition, the relative abundance of phyla, genera, and species 
per sample were plotted (supplemental Figure 2-S3). 
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Figure 2-S3. Relative abundance of phyla (S3A), genera (S3B) and species (S3C) per 
individual sample. A and B before sample numbers indicate the synbiotic and placebo 
groups, respectively. 
 
The data obtained confirmed that Firmicutes and Bacteroidetes were the two most 
abundant bacterial phyla in the gut (see Figure 2-1A) and Bacteroides was the most 
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abundant genus (see Figure 2-1B). The synbiotic supplementation induced statistically 
significant alterations in the composition of the gut microbiota at the end of trial, as 
compared with the placebo group (Figure 2-2). All data were remained significant after 
adjusting for multiple testing (supplemental Table 2-S5). At the phylum level, increases 
in relative abundance of Cyanobacteria, Euryarchaeota, Fusobacteria, and 
Lentisphaerae were observed following synbiotic intervention. At the genus level, 
relative abundance of Ruminococcus, Bifidobacterium, Sutterella, Tyzzerella, 
Eisenbergiella, Eubacterium, Eggerthella, Methanobrevibacter, Lachnospiraceae, 
Edwardsiella, Lactobacillus, Allobaculum, Enterococcus, Hydrogenoanaerobacterium, 
Coprococcus, and Butyricimonas were significantly higher. The relative abundance of 
Ruminococcaceae, Prevotella, Gardnerella, Turicibacter, and Megasphaera at the end of 
trial was significantly lower in the synbiotic group, as compared with the placebo group. 
These results indicate that the synbiotic supplement used in the study modified relative 
abundance of gut bacteria, some of which can be associated with health benefits 
(particularly, significantly increased abundance of Bifidobacterium and Lactobacillus). 
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Figure 2-1. Mean relative abundance (%) of phyla (A) and genera (B) by the treatment 
groups and time points. 
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Figure 2-2. Changes in the relative microbial abundance in the gut after synbiotic 
intervention. *p < 0.05, **p < 0.01, ***p < 0.001, as compared with the placebo group at the 
end of trial. 
Gut microbiota p-value 
Megasphaera                     0.003 
Prevotella 2           0.001 
Turicibacter           0.004 
Gardnerella           0.0001 
Prevotella 9     0.001 
Ruminococcaceae UCG-011  0.019 
Butyricimonas 0.0001 
Coprococcus 2 0.007 
Hydrogenoanaerobacterium 0.018 
Enterococcus 0.001 
Allobaculum 0.002 
Eubacterium ruminantium group 0.008 
Lactobacillus 0.041 
Edwardsiella 0.001 
Lachnospiraceae ND3007 group 0.012 
Methanobrevibacter 0.015 
Eggerthella 0.001 
Eubacterium oxidoreducens group 0.011 
Eisenbergiella 0.009 
Tyzzerella 4 0.005 
Sutterella 0.013 
Bifidobacterium 0.004 
Ruminococcus 2 0.003 
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Ruminococcus 1 0.002 
Lentisphaerae 0.037 
Fusobacteria 0.037 
Euryarchaeota 0.022 
Cyanobacteria 0.047 
Table 2-S5. Bonferroni adjusted P-values. The Bonferroni correction sets the 
significance cut-off at α/n. With 28 tests (gut microbiota, n=28) and (α= 0.05), we'd only 
reject a null hypothesis if the p-value is less than 0.0017. 
 
Alpha diversity metrics were used to measure species richness and evenness 
(similar abundance) in the groups (Figure 2-3 and Table 2-2). The number of OTUs, the 
Chao1 estimator (a measure of community richness), and the Shannon Index (a measure 
of richness and evenness or entropy) were calculated. Data analysis showed that there 
were no significant differences in alpha diversity metrics between treatment groups and 
time points (Figure 2-3B). Shannon index pointed to a decreasing trend in microbial 
diversity at the end of trial in both the placebo and synbiotic groups (Figure 2-3C). This 
data suggests that the observed decrease in microbial diversity in the placebo and 
synbiotic groups at the end of trial implies involvement of other factors, probably, the 
effect of the high-protein, low-carbohydrate, energy-restricted diet used in this weight 
loss program. 
46 
 
 
Figure 2-3. Observed species (A), Chao1 diversity (B) and Shannon diversity (C) plotted 
by the treatment group and time point. The box spans the first and third quartiles. A 
horizontal line marks the median and the whiskers represent ±1.5-times the interquartile 
range. Outliers (panels A and B) are marked as individual points. Significant differences 
between groups were determined using the estimated marginal means analysis applied to 
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linear mixed model, which was built with alpha diversity as the response variable, the 
treatment group and time points as predictor variables, and subject number as a random 
variable. 
Groups Shannon Index Chao1 Diversity Observed Species 
Within  Between  Estimate p-value Estimate p-value Estimate p-value 
Baseline Placebo - Synbiotic 0.144 0.643 295.0 0.359 222.0 0.388 
End of Trial Placebo - Synbiotic 0.145 0.641 205.4 0.521 180.9 0.481 
Placebo Baseline - End of Trial 0.208 0.208 76.94 0.577 76.20 0.460 
Synbiotic Baseline - End of Trial 0.209 0.206 -12.65 0.927 35.10 0.732 
Table 2-2. Measuring statistically differences in alpha diversity between groups. Three 
alpha diversity metrics were used (Shannon Index, Chao1 Estimator, and Observed 
Species/OTUs). Significant differences between groups were determined using the 
estimated marginal means analysis applied to linear mixed model, which was built with 
alpha diversity as the response variable, the treatment group and time points as predictor 
variables, and subject number as a random variable. 
 
Beta diversity metrics were used to compare differences in the community 
composition of two different samples. Bray-Curtis dissimilarity was used to compare the 
abundance of each OTU between two samples to give a metric between 0 and 1; 
weighted UniFrac distance, which is a dissimilarity metric that uses the phylogenetic 
distribution of the OTUs in a sample together with the abundance of those OTUs to 
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measure the distance between two samples; and unweighted UniFrac distance, which also 
measures the phylogenetic distribution of the OTUs in a sample, but relies only on 
presence/absence data instead of abundance data [158]. An assessment of the distances 
within and between time points and groups did not reveal significant changes in the 
community structure (Table 2-3). 
 
Groups  Bray-Curtis 
Dissimilarity 
Weighted UniFrac Unweighted 
UniFrac 
Within  Between F-model p-value F-model p-value F-model p-value 
Baseline Placebo - Synbiotic 1.393 0.133 0.840 0.516 1.155 0.232 
End of Trial Placebo - Synbiotic 1.389 0.158 0.923 0.379 1.038 0.325 
Placebo Baseline - End of 
Trial 
0.376 0.996 0.389 0.932 0.351 1.000 
Synbiotic Baseline - End of 
trial 
0.431 0.983 0.305 0.958 0.392 1.000 
Table 2-3. Measuring statistical significant of beta diversity differences between groups 
using Permutational Multivariate Analysis of Variance (PerMANOVA) on models with 
beta diversity as the response variable, and treatment group and time point as predictive 
variables. Three beta diversity metrics were used (Bray-Curtis, weighted UniFrac, and 
unweighted UniFrac). 
To visually identify whether groups of samples cluster based on similarity to each 
other, PCoA plots were generated to highlight separation of groups of samples for 
unweighted UniFrac distance, weighted UniFrac distance, and Bray-Curtis dissimilarity 
distance (Figure 2-4). No statistically significant differences in microbial diversity 
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between or within the placebo and synbiotic group at the baseline and end of trial were 
observed. 
 
Figure 2-4. Principal Coordinates Analysis (PCoA) of unweighted UniFrac (A), weighted 
UniFrac (B) and Bray-Curtis dissimilarity data (C). Scatter plots show principal 
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coordinate 1 (PC1) vs. principal coordinate 2 (PC2) with percentages of variation 
explained by the components indicated. Points are colored by the treatment group and 
time point. 
2.3.3. Associations between gut microbiota, body composition and metabolic 
parametersIn order to explore associations between the gut microbial species and body 
composition and metabolic parameters, regression and correlation analyses were 
performed as described in the Methods section. Regression analysis to correlate relative 
microbial abundance of species present in the synbiotic supplement with body 
composition parameters and biomarkers of obesity found association between a decrease 
over time in blood glucose and an increase in Lactobacillus abundance in the synbiotic 
and placebo groups. In both groups combined, a mean decrease in HbA1C% (5.85%, see 
Table 1) was accompanied by a mean increase in Lactobacillus abundance (24.1-fold, see 
Fig. 2; p = 0.044). However (and somewhat paradoxically), a decrease over time in body 
mass, BMI, waist circumstance, and body fat mass was associated with a statistically 
significant decrease in Bifidobacterium abundance in both the placebo and synbiotic 
groups (Table 2-4). 
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Parameters Change Gut microbiota Change P 
HbA1C% ↓ 5.85% Lactobacillus ↑ 24.1- fold 0.044 
Body mass (kg) ↓ 7.86% Bifidobacterium ↓ 263.8- fold 0.052 
BMI (kg/m2) ↓ 7.98% Bifidobacterium ↓ 263.8- fold 0.009 
WC (cm) ↓ 5.90% Bifidobacterium ↓ 263.8- fold 0.023 
Body Fat Mass (kg) ↓ 7.89% Bifidobacterium ↓ 263.8- fold 0.011 
Table 2-4. Association between changes over time in (body composition and metabolic 
parameters) and changes in gut microbiota abundance in the synbiotic and placebo groups 
(both groups combined). BMI, Body Mass Index; WC, Waist Circumference; HbA1C, 
glycated hemoglobin. Data was generated by applying analysis of variance to a mixed 
linear model, built with the abundance of a given microbe as the response variable, and 
body composition, metabolic parameter, treatment groups and time points as the predictor 
variables, with subject number as random variable. 
The Pearson’s linear correlation test (Figure 2-5) did not indicate statistically 
significant associations between Bifidobacterium and Lactobacillus abundance and body 
composition parameters in the synbiotic group at the end of trial. A negatively correlated 
trend was observed between Bifidobacterium abundance and HbA1C levels in the 
synbiotic and placebo groups, whereas a positively correlated trend between 
Bifidobacterium abundance and, to a lesser extent, Lactobacillus abundance was 
observed with BMI, WC, and body fat mass in the synbiotic group. Interestingly, in the 
placebo group, Lactobacillus abundance was negatively correlated with body fat mass. 
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Cyanobacteria, Sutterella, Butyricimonas, and Eubacterium ruminantium 
abundance (which were increased following the synbiotic intervention) were significantly 
negatively correlated with body fat mass, and Cyanobacteria and Sutterella abundance 
was negatively correlated with body fat percentage. Additionally, Butyricimonas 
abundance positively correlated with BMC. Eubacterium abundance positively correlated 
with HbA1C percentage, whereas Megasphaera abundance (which was decreased after 
the synbiotic intervention) was negatively correlated with this marker. Positive 
correlations were found between Coprococcus abundance and body mass, BMI, and WC; 
Lachnospiraceae abundance and BMI, WC, and body fat mass; Tyzzerella and 
Gardnerella abundance and WC. 
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Figure 2-5.  Heatmap of associations between gut microbiota, body composition and 
metabolic parameters in the placebo (A) and synbiotic groups (B) at the end of trial. r 
values were calculated using Pearson’s linear correlation test; *p  < 0.05, **p  <0.01. 
Pearson’s r values below 0.30 or above -0.30 are not indicated. Red-brown color 
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indicates negative correlation, blue-green color -- positive correlation.Our data confirmed 
several previously reported associations [159-161], however, correlations found for 
Lactobacillus and Bifidobacterium were somewhat unexpected, although appear to be 
promising for associations with blood glucose levels. The results obtained support the 
conclusion that the synbiotic supplement used in this intervention trial modulated the 
microbiota by increasing abundance of the microbial genera associated with beneficial 
effects. Furthermore, these microbial changes may be associated with positive effects on 
metabolic parameters (blood glucose) in obesity. 
2.4. Discussion 
This study was a placebo-controlled intervention clinical trial designed to 
examine the effects of a combination of probiotic bacteria L. acidophilus, B. lactis, B. 
longum, B. bifidum and a prebiotic mixture of galactooligosaccharides on the human gut 
microbiota in relation to changes in body composition and metabolic biomarkers in obese 
human subjects enrolled on a weight loss program. The weight loss program was a high-
protein, low-carbohydrate, energy-restricted eating plan. Previous limited studies 
conducted using L. acidophilus and B. lactis have found that these probiotic species can 
be associated with decreased body weight and body fat percentage [162], while prebiotic 
galactooligosaccharides have been shown to improve markers of metabolic syndrome and 
modulate the gut microbiota and immune function in overweight adults [153, 163, 164]. 
However, this study focused on evaluating the effects of synbiotic supplementation in 
obesity during weight loss intervention. 
The study has confirmed that a high-protein, low-carbohydrate, restricted-energy 
diet can be effectively used for weight loss in obese individuals, but it also confirmed that 
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such a diet is associated with specific changes in gut microbiota. Previous evidence has 
shown that synbiotic supplementation contributes to altering microbial composition, 
resulting in benefits to weight loss and maintenance [165]. In the current study 
supplementation resulted in microbial changes that have frequently been associated with 
benefits to host health. However, how these changes relate to metabolic health remains to 
be confirmed. Furthermore, the microbial breakdown of proteins within the large 
intestine has been associated with the production of genotoxic and cancer associated 
metabolites, e.g. N- nitroso compounds and ammonia [144]. As such, altering the gut 
community to one less proteolytic through the introduction of a synbiotic could be of 
benefit to the host. 
A combination of the four strains of Bifidobacterium and Lactobacillus 
acidophilus in the synbiotic supplement resulted in a significant increase in abundance of 
these probiotic genera in the gut after a 3-month intervention. Bifidobacterium is largely 
considered a positive member of the microbial community and furthermore, there has 
been some association with anti-obesity effects [162, 166, 167]. In addition to this, 
further modulation of the microbiota was observed, for example, Prevotella and 
Gardnerella genera were significantly decreased after the synbiotic intervention (see 
Figure 2-2). Previous studies have reported that these genera are associated with chronic 
inflammatory conditions and positively correlated with obesity [168-170]. Therefore, the 
reduction in these genera could help to modulate the balance to improve metabolism 
within the host. Special caution is warranted when analyzing the data referring to 
Prevotella, a complex genus linked both to health and disease and maybe influenced by 
race/ethnicity [171]. However, statistically significant differences in the community 
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composition of gut microbiota between groups (synbiotic vs. placebo) and time points 
(end vs. beginning of trial) using parameters of alpha-diversity (see Table 2-2) and beta-
diversity (see Table 2-3) were not observed. Our data is compatible with a recent study 
that did not found a relationship between severe caloric restriction and changes in alpha-
diversity[172]. In addition, correlation and regression analyses did not indicate 
statistically significant or apparently beneficial associations between species contained in 
the synbiotic supplement (Bifidobacterium and Lactobacillus) and body composition 
parameters, including at the end of synbiotic intervention (see Figure 2-5B). Interestingly, 
the changes over time in body mass, BMI, waist circumstance, and body fat mass 
demonstrated a positive correlation trend with Bifidobacterium abundance in the 
synbiotic group, while changes in body fat mass were negatively correlated with 
Lactobacillus abundance in the placebo group. However, positive associations between 
relative abundance of Bifidobacterium and several body composition parameters appear 
to point to the unfavorable role of these bacteria in promoting weight loss, although any 
potential benefits of this genera could be masked by the high-protein diet used in the 
study. High protein intake induces proteolytic fermentation in the gut with synthesis of 
compounds that have been implicated in the development of obesity and metabolic 
syndrome and modulating the gut microbiota [140-142, 173] and the production of toxic 
metabolites [174]. Several studies have also found that an increase in Bifidobacterium 
and Lactobacillus abundance is correlated with both pro- and anti-obesity effects in obese 
human subjects [175, 176], thus complicating the interpretation of the results. Individual 
differences in energy extraction may contribute to explain the observed differences [177]. 
Additionally, Bifidobacterium have been linked with improved barrier function in 
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overweight individuals, thus adding a potential beneficial mechanism of action [81]. 
Therefore, more studies are needed to fully understand the observed divergences and 
correctly identify human subpopulations susceptible to benefit from synbiotic 
intervention. 
Regression analysis performed to correlate microbial abundance of species 
contained in the synbiotic supplement with biomarkers of obesity found a novel 
significant association between a decrease over time in HbA1C percentage and an 
increase in Lactobacillus abundance, particularly in the synbiotic group. This is an 
important observation because it demonstrates the beneficial effect of increasing 
Lactobacillus abundance on potentially reducing blood glucose levels. Negative 
associations between Megasphaera abundance and Eubacterium ruminantium abundance 
with HbA1C levels were observed in the synbiotic group at the end of trial. Eubacterium 
ruminantium are xylanolytic bacteria (i.e., producing xylanase following dietary fiber 
fermentation) and Megasphaera bacteria utilize lactate [178], which can underlie 
potential relationship of these species to decreasing blood glucose levels [179, 180]. 
However, within the trial following the synbiotic a decrease in Megasphera was 
observed, an increase in Eubacterium ruminantium. This could imply that the synbiotic 
intervention and associated microbial changes could be linked to maintaining a normal 
blood glucose levels in obesity. 
It should also be considered that the microbial shifts observed in this study may 
be associated with a positive impact on microbial fermentation within the large intestine. 
Whilst the microbial changes observed following synbiotic intervention included an 
increase in Ruminococcus, a genera known to produce butyrate. Butyrate is a short chain 
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fatty acid that provides and energy source for the colonocytes, as a histone deacetylase 
inhibitor this SCFA is linked to anti-cancer effects, hence could offer protection against 
some of the metabolites that are produced within a high protein diet. SCFA’s have also 
recently been associated with protection against type 1 diabetes [181]. In addition to this 
lactobacilli and bifidobacteria are associated with positive effects of colonic health and 
following synbiotic intervention have been associated with reducing fecal water 
genotoxicty, which is considered a biomarker for colon cancer [182]. Therefore, whilst 
within the weight-loss diet employed the synbiotic treatment may have had a limited 
impact on the weight-loss parameters, it is possible that the changes in the microbiota 
could help to reduce detriments associated with a high protein diet. 
It is important to emphasize that the present study was a randomized, placebo-
controlled intervention clinical trial and that analysis of the community composition of 
the gut microbiota between the treatment groups and time points was performed using 
comprehensive microbiome analysis, including alpha- and beta-diversity metrics and 
multivariate analysis of variance. The design of the study has allowed us to detect 
important novel associations between composition of the gut microbiota and metabolic 
parameters in obesity in the relatively limited number of participants in this clinical trial. 
The results obtained and bioinformatic analysis support the conclusion that weight 
loss in human subjects participating in a high-protein, low-carbohydrate, energy-
restricted eating weight loss program is accompanied by changes in gut microbiota that 
can be associated with increased genotoxicity [144]. The synbiotic used in this study 
modulated the human gut microbiota by increasing abundance of the microbial species 
that can be considered to be of benefit to their host; it was also associated with positive 
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effects on metabolic parameters in obesity. Thus, the addition of synbiotic supplements to 
weight reduction diets may aid against negative microbial changes associated with high 
protein diets and weight loss. 
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Abstract: Targeting gut microbiota with probiotics has recently emerged as a promising 
nutritional approach for the prevention of obesity and metabolic syndrome. Cultured 
dairy products can be effectively employed for the delivery of probiotics to the gut as 
well as for the support of growth and survival of probiotic bacteria. The purpose of this 
study was to characterize the effects of probiotic-enriched pasteurized milks and dairy 
products (Greek-style yogurt and cheese) of different origins (cow, goat, and camel) on 
the taxonomic composition of the mouse gut microbiota and body weight. Mice were fed 
standard low fat, plant polysaccharide-rich (LF/PP) diet supplemented with the probiotic-
enriched dairy products for 5 weeks. Next generation DNA sequencing from mouse fecal 
samples was used to obtained data on the bacterial relative abundance. Mice fed a diet 
supplemented with camel milk demonstrated a decrease in body weight gain as compared 
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with mice fed LF/PP diet. This was accompanied by characteristic changes in the gut 
microbiota, which included an increase in relative abundance of order Clostridiales and 
genus Anaerostipes. Mice fed diet supplemented with the probiotic cheese exhibited a 
decreasing trend in body weight gain, accompanied by an increase in the relative 
abundance of order Clostridiales, family Ruminococcaceae, and family Lachnospiraceae. 
The results obtained and their bioinformatics analysis support the conclusion that camel 
milk and probiotic cheese induce changes in the mouse gut microbiota, which can be 
characterized as potentially health beneficial compared to changes associated with 
standard diet or diets supplemented with cow milk, goat milk, and yogurt. These findings 
imply that dairy products are effective for the delivery and supporting growth of 
probiotics bacteria in the gut and, thus, may contribute to maintaining healthy body 
weight. 
 
Keywords: gut microbiota; cultured dairy products; probiotic-enriched dairy products; 
body weight  
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3.1. Introduction 
Over the last decade an ever growing body of evidence has established the gut 
microbiota as one of the most important determinants of metabolic syndrome [183-185]. 
Importantly, the gut microbiota composition is modulated by several genetic and 
environmental factors, including diet among the most important factors [186-188]. 
Therefore, manipulation of the gut microbiota through dietary intervention and probiotic 
supplements can be a promising strategy for the prevention and treatment of metabolic 
syndrome and obesity. As a consequence, worldwide sales of probiotics have more than 
doubled in the last decade alone [114]. Probiotic bacteria can be delivered to the gut as 
dietary supplements or in foods, including dairy products, such as yogurt or kefir [115, 
116].  
More than 6 billion people worldwide consume milk and dairy products [189]. 
Milk provides 11 to 14 percent of dietary energy supply in Europe, Oceania and the 
Americas [190]. Recent studies have found an inverse relation between consumption of 
dairy products and metabolic syndrome and, probably, obesity [191, 192]. 
We hypothesized that cultured dairy products such as cheese and yogurt can be an 
ideal vector for the delivery of probiotics to the gut because of its nutritional value, acidic 
nature, and long shelf-life. Cheese is a suitable matrix for transferring probiotic bacteria 
into the gastrointestinal tract due to the high buffering capacity of the milk proteins which 
can protect the bacterial cells during transit. High fat content and dense structure of 
cheese protect bacteria against acidic environment of the gastrointestinal tract [117-119]. 
While several studies have shown an inverse association between dairy products and 
metabolic syndrome and obesity [120-122], studies that comprehensively analyze the 
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effects of different milk sources (cow, goat and camel) and products (milk, yogurt, 
probiotic yogurt, cheese, and probiotic cheese) on the gut microbiota composition and 
body weight are not available. 
The objective of this study was to characterize the effect of probiotic-enriched 
pasteurized milk, Greek-style yogurt, and cottage cheese made from milk of different 
origins (cow, goat, and camel) on the taxonomic composition of the mouse gut 
microbiota and body weight. A well-established Clostridium butyricum [193, 194] was 
used as probiotic in these studies. The results obtained and their bioinformatics analysis 
appear to support the conclusion that camel milk and the probiotic cow cheese induce 
changes the mouse gut microbiota, which are associated with the optimal weight gain in 
growing mice. 
 
3.2. Materials and Methods 
3.2.1. Animals and diets 
Female 6-8 weeks old C57BL/6 mice weighing 14-16 g, were purchased from 
Jackson Laboratory (Bar Harbor, ME). Upon arrival, they were randomly grouped and 
kept in specific pathogen free (SPF) conditions in individually ventilated cages with 
sterile bedding at 24-26°C, relative humidity 50 ± 10% and a 12-h light/dark cycle. Mice 
were fed ad libitum standard low fat, plant polysaccharide-rich (LF/PP) diet 5001 
(LabDiet, St. Louis, MO) supplemented daily with the dairy products for 5 weeks. The 
control group was fed standard LF/PP diet without dairy supplementation. Three groups 
were supplemented with pasteurized cow milk (DairyPure, Dallas, TX, USA), goat milk 
(Meyenberg, Turlock, CA, USA) or camel milk (Desert Farms, Santa Monica, CA). Four 
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groups were supplemented with cow yogurt or goat yogurt (with and without probiotics). 
Finally, two groups were fed diet supplemented with either a regular cow cheese or a 
probiotic cow cheese. There were 5 animals in each experimental group. The amount of 
daily supplementations was 1 mL of dairy product per mouse per day. Body weight was 
measured weekly using top-loading balances with 0.01 g precision (OHAUS SPX222., 
Pine Brook, NJ). The experiments were approved by the South Dakota State University 
Institutional Care and Use Committee (Approval number: 16-024A). 
 
3.2.2. Manufacture of Cultured Dairy Products 
The probiotic cheese and probiotic yogurt were manufactured at the Health and 
Nutritional Sciences Department facilities utilizing the probiotic strains grown in our 
laboratory. The manufacture process for Greek-style yogurt and cottage cheese is 
schematized in Figure 3-1, following the procedure described elsewhere [195, 196]. One 
liter of yogurt and cottage cheese were produced weekly. 
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Figure 3-1. Schematic diagram for the manufacture of cultured dairy products: (a) 
Greek-style yogurt and (b) cottage cheese. 
 
3.2.3. Microbial DNA Extraction and the 16S rRNA Gene Sequencing 
Fecal samples from mice were obtained at the end of experimental study by 
taking individual mice out of their cage and gathering a stool sample in a 2 mL tube. All 
fecal samples were immediately frozen at -80°C. DNA was extracted from fecal sample 
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by using the microbial DNA extraction method (ZR Fecal DNA MiniPrep™) as 
described by [197]. Libraries and sequencing were performed at the South Dakota State 
University Genomics Sequencing Facility. Amplification of the V3-V4 amplicon (460bp) 
of the 16S RNA gene was achieved using primers described in Klindworth et al. [198]: 
16SAmpliconPCRForwardPrimer = 
5'TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG 
16SAmpliconPCRReversePrimer = 
5'GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTA
ATCC. These primers include the Illumina overhang adapter sequences in their 5’ ends. 
Amplification was carried out using KAPA HiFi HotStart Ready Mix (KAPABiosystems. 
Wilminton, MA) using the following polymerase chain reaction (PCR) thermal profile: 
3min @ 95C, 25 cycles (30sec @ 95C, 30 sec @ 55C, 30 sec @ 72C), 5 min @72C. 
PCR clean-up was done with a SMARTer Apollo system (Takara Inc. Mountain View, 
CA) using AMPure XP beads (Beckman Coulter. Indianapolis, IN). A second round of 
PCR amplification was carried out to introduce individual Nextera XT (Illumina Inc. San 
Diego, CA) indices in each library. This second amplification was carried out using 
KAPA HiFi HotStart Ready Mix (KAPABiosystems. Wilminton, MA) using the 
following PCR thermal profile: 3min @ 95C, 8 cycles (30sec @ 95C, 30 sec @ 55C, 
30 sec @ 72C), 5 min @72C; PCR clean-up was done the same way as described for 
the first PCR round. Sequencing was carried out in an Illumina MiSeq using vs 3 
chemistry (3x300 bp). 
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3.2.4 Bioinformatics and Statistical analyses 
All bioinformatics analyses were performed using the Microbial Genomics 
Module in CLC Genomics Workbench vs 12.0 (Qiagen). After trimming adaptors and 
lower quality reads (q=20) the pared reads were joined. Samples with less than 90,000 
reads were removed from further analysis. Resulting operational taxonomic units (OTUs) 
were aligned to the GrainGenes database vs 13_5 at 97% similarity. Individual OTUs 
with less than 100 reads were removed from further analysis. All samples underwent 
taxonomic classification and were included in the complete OTU table (supplemental 
Table 3-S2). Statistical comparisons between group pairs were carried out using a Wald 
test; p values were False Discovery Rate (FDR) corrected. 
For the body weight, differences between groups were determined by ANOVA, 
followed by the Fisher’s multiple comparison procedure to identify differences in 
treatment means. The results were expressed as means ± S.E.M. Mean differences were 
considered significant at p < 0.05. Data were analyzed using SPSS 20.0. 
3.3. Results 
3.3.1. Effect of probiotic-enriched camel, cow, and goat milk on the gut microbiota 
profiles and body weight gain 
The effect of different milks on body weight is shown in Figure 3-2. Mice were 
feed a standard LF/PP diet supplemented with the dairy products for 5 weeks. Mice in the 
group supplemented with cow milk demonstrated a small, but significant (p=0.004) 
weight gain when compared with the control group. However, mice fed diets 
supplemented with either goat or camel milk did not have a significant body weight gain 
compared to control animals. 
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Analysis of fecal samples for changes in the gut microbiota in different 
experimental groups is presented in Figure 3-3. Next generation gene sequencing of 16S 
rRNA (3x300bp PE V3 + V4) from fecal samples was used to obtain data on the bacterial 
relative abundance, which was analyzed at the level of order, family, and genus. The 
groups supplemented with different milks were then compared. A significant reduction in 
the relative abundance of order Clostridiales 191753 (p=0.01), Clostridiales 4455677 
(p=0.02), family Clostridiaceae 268074 (p=0.02), and family Peptostreptococcaceae 
276478 (p=0.01) was observed in the group supplementd with cow milk, while an 
increase of order Clostridiales 199532 (p=0.03), Clostridiales 271602 (p=0.001), and 
genus Anaerostipes 534926 (p=0.02) was demonstrated in the group supplemented with 
camel milk as compared with the group supplemented with cow milk (Figure 3-3A). We 
also found that the relative abundance of family Clostridiaceae 268074 and  
Peptostreptococcaceae 276478 was significantly decreased in the camel milk group as 
compared with the goat milk group (p=0.003 and p=0.003), respectively (Figure 3-3B). 
The relative abundance of order Clostridiales 271602 and genus Anaerostipes 534926 
was significantly higher in the goat milk group compared with the cow milk group 
(p=0.03 and  p=0.03), respectively, while a reduction in order Clostridiales 344198 
(p=0.0003) was founded in animals supplemented with goat milk compared with the cow 
milk group (Figure 3-3C). 
A Venn diagram was established to clarify the overlap of OTUs (enriched for 
certain OTUs) between the camel, cow, and goat milk supplemented groups. The total 
significant richness in the dataset was 17 OTUs, with the most changes observed in the 
camel milk group vs. the cow milk group (9 total OTUs) (Figure 3-4). We also observed 
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that the body weight gain in the camel milk group exhibited a decreasing trend at day 21 
and 35 (see Figure 3-2). These findings suggest that the gut microbiota enrichment can 
be achieved via consumption of camel milk. 
 
 
 
Figure 3-2. Percentage of body weight increase in mice fed diets supplemented with 
cow, goat, or camel milk. Data are presented as mean ± SEM. n=5 per group. *p < 0.05, 
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as compared between the indicated groups and determined by ANOVA. 
 
Figure 3-3. Relative abundance of the gut microbiota at the order (o), family (f), and 
genus (g) levels, as compared between the camel milk vs. cow milk groups (A), camel 
milk vs. goat milk groups (B), and goat milk vs. cow milk groups (C). FDR p-value are 
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*p < 0.05, **p < 0.01, and ***p < 0.001.
 
Figure 3-4. The overlap (enrichment) of microbial species (OTUs) between the camel, 
cow, and goat milk groups. The numbers indicate overlap in OTUs.  
3.3.2. Effects of probiotic-enriched yogurt and cheese on the gut microbiota profiles 
and body weight gain 
The effects of probiotic-enriched yogurt and cheese of different origins (cow and 
goat milk) on the gut microbiota and body weight were determined. Mice were fed LF/PP 
diet supplemented with the probiotic dairy products for 5 weeks. Figure 3-5 shows that 
the body weight gain of the probiotic cow cheese group exhibited a decreasing trend at 
day 28 (p=0.08) and day 35 (p=0.07). The probiotic goat yogurt group demonstrated a 
significant body weight gain compared to the probiotic cow cheese group (p=0.01) and 
the cow cheese groups (p=0.03) at day 28. Individual body weight (g) and time (days) 
measurements of mice fed diet supplemented with dairy products, are presented in 
appendix Table 3-S1. 
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Fecal samples were analyzed for changes in the gut microbiota of mice in the 
experimental groups (Figure 3-6). The relative abundance of the order Clostridiales, 
family Lachnospiraceae, genus SMB53, and species Ruminococcus gnavus were 
significantly higher in the probiotic cow yogurt group vs. the cow yogurt group, while a 
decrease in relative abundance of family Erysipelotrichaceae, Clostridiaceae, genus 
Oscillospira, Clostridium, Ruminococcus, Aerococcus, species R. gnavus and  
Clostridium perfringens  were observed comparing the same groups (see Figure 3-6A). 
Changes in the bacterial relative abundance were observed in comparisons 
between the probiotic goat yogurt group and the goat yogurt group. A significant 
decrease in abundance of order Clostridiales and family Lachnospiraceae were observed, 
while relative abundance of order Clostridiales, genus Staphylococcus, Anaeroplasma, 
Anaerostipes, and species R. gnavus was increased (see Figure 3-6B). 
In the probiotic cow cheese group vs. the cow cheese group (Figure 3-7), the 
relative abundance of order Clostridiales, family Ruminococcaceae, S24-7, 
Lachnospiraceae, and species R. gnavus was significantly higher, whereas a decrease in 
relative abundance of order Clostridiales, family Erysipelotrichaceae, Lachnospiraceae, 
S24-7, genus Coprococcus, Oscillospira, and species R. gnavus was observed. 
A Venn diagram was established to determine the overlap of OTUs between the 
yogurt and cheese groups (Figure 3-8). The total significant richness in the dataset was 
found for 16 OTUs in the cow yogurt group (Figure 3-8A), 13 OTUs in the goat yogurt 
group (Figure 3-8B), and 30 OTUs in the cow cheese group. The most significant 
enrichment was found in the probiotic cow cheese group vs. the cow cheese group (30 
total OTUs) (Figure 3-8C). These findings suggest that the gut microbiota enrichment 
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can be linked to consumption of the probiotic cow cheese and imply that this cheese can 
be an efficient vector for the probiotic delivery. 
 
 
Figure 3-5. Percentage of body weight increase in mice fed diets supplemented with 
yogurt and cheese. Data are presented as mean ± SEM. n=5 per group. *p < 0.05 and 
§p < 0.08 (approaching significance), as compared between the indicated groups and 
determined by ANOVA.  
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Figure 3-6. Relative abundance of the gut microbiota at the order (o), family (f), genus 
(g), and species levels (s), as compared between the probiotic cow yogurt group vs. the 
cow yogurt group (A) and the probiotic goat yogurt group vs. the goat yogurt group (B). 
FDR p-value are *p < 0.05, **p < 0.01, and ***p < 0.001. 
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Figure 3-7. Relative abundance of the gut microbiota at the order (o), family (f), genus 
(g), and species levels (s), as compared  between the probiotic cow cheese group vs. the 
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cow cheese group. FDR p-value are *p < 0.05, **p < 0.01, and ***p < 0.001.  
 
 
Figure 3-8. The overlap (enrichment) of microbial species (OTUs) between the yogurt 
and cheese supplemented groups. The numbers indicate overlap in OTUs. 
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3.4. Discussion 
The present studies demonstrated that gut microbiota enrichment can be achieved 
via consumption of camel milk, as compared with cow and goat milk. In addition, a 
significant gut microbiota enrichment was observed in mice supplemented with the 
probiotic cow cheese. To the best of our knowledge, this is the first study that compared 
the effects of supplementation with dairy products originating from different animals on 
the gut microbiota composition. 
The findings obtained indicate that, when compared with mice fed with cow milk, 
mice fed a diet supplemented with camel milk demonstrate a decrease in body weight 
gain (see Figure 3-2) accompanied by characteristic changes in the gut microbiota, 
including an increase in order Clostridiales and genus Anaerostipes (see Figure 3-3A). 
Importantly, these bacteria have been previously shown to produce short-chain fatty acids 
(SCFAs), a bacterial fermentation product of dietary fiber, recognized to have wide-
ranging effects on maintenance of health and host physiology [199-201]. We also found a 
decreased abundance of Peptostreptococcaceae bacteria in the camel milk group. 
Importantly, species in this family are positively associated with obesity and 
inflammation [202-204]. 
The health benefits of camel milk may be partly explained by its functioning as a 
prebiotic. Camel milk has a high overall nutritional value and high heat stability in the 
process of preservation of raw milk by pasteurization [205, 206]. The induction of the 
SCFAs producing gut bacteria via consumption of camel milk may lead to development 
of nutritional strategy for weight loss and the prevention and treatment of obesity. 
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Surviving passage over the host’s gastrointestinal tract is a critical event for any 
probiotic. In this regard, we observed that the total significant richness in the dataset were 
16 OTUs for the probiotic cow yogurt group vs. the cow yogurt, 13 OTUs for the 
probiotic goat yogurt group vs. the goat yogurt group, and 30 OTUs for the probiotic cow 
cheese group vs. the cow cheese group (see Figure 3-8C). These results indicate that the 
probiotic supplement used in the study modified relative abundance of gut bacteria, some 
of which can be associated with health benefits (particularly, a significantly increased 
abundance of order Clostridiales due to the probiotic intervention; see Figure 3-7). 
Therefore, cheese appears to be a suitable matrix for transferring probiotic bacteria into 
the gastrointestinal tract, probably, due to the high buffering capacity of milk proteins 
which will protect the microbial cells during transit (dense product structure may also 
protect the bacteria against the acidic environment in the gastrointestinal tract [117-119]). 
Clostridium butyricum supplementation triggered a shift in body weight gain with 
a significant decrease in the probiotic cow cheese group compared with the probiotic goat 
and cow yogurt groups (see Figure 3-5). We also found that the addition of this probiotic 
to cow cheese improves gut microbiota manifesting in an increase in the relative 
abundance of order Clostridiales, family Ruminococcaceae and Lachnospiraceae (see 
Figure 3-7). These bacteria have been previously shown to produce butyrate [207, 208]. 
Butyrate (one of the main SCFAs) may be protective from developing of obesity and 
metabolic disorder [181, 209]. Additionally, this probiotic in cheese was associated with 
a significant reduction on the family Erysipelotrichaceae and genus Coprococcus. The 
Erysipelotrichaceae  abundance is high in obese individuals [210]. Furthermore, the 
relative abundance of Coprococcus is increased by high-fat diet [211]. These are 
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important considerations because they suggest the beneficial effect of the probiotic cow 
cheese supplementation on maintaining normal body weight gain and facilitating weight 
loss in obesity. 
Overall, the results obtained and their bioinformatics analysis appear to support 
the conclusion that camel milk and cow cheese enriched with Clostridium butyricum 
probiotic are associated with potentially health beneficial changes of the mouse gut 
microbiota. The findings also suggest that the consumption of camel milk and the 
probiotic cow cheese may have beneficial effects on body weight gain, thus, providing 
the basis for future clinical trials to investigate their effects in prevention of obesity. 
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CHAPTER 4. Effects of Food at Home vs. Food Away from Home-Induced Changes 
on Gut Microbiota and Immunological Status in Diabetes 
 
Abstract: Gut microbiota dramatically affects our nutritional and immunological status. 
However, linking diet to the structure and dynamic operation of microbial communities 
and to human biology and pathobiology has proven elusive because of numerous 
uncontrolled genetic and environmental variables. To study whether the food at home 
(FAH), can help to reduce risk of developing diabetes by increasing abundance of the 
beneficial bacteria, T regulatory (Treg) cells, and decreasing in inflammation-associated 
bacteria, IL-17 producing cells, and blood glucose levels, 12 healthy volunteers were 
randomly assigned into two diets, one based on food away from home (FAFH) and the 
other on food at home (FAH). Two weeks later, fecal samples of the volunteers were 
collected and analyzed, then transferred into antibiotic and non-antibiotic treated mice, 
and their resistance to develop diabetes was measured. The results obtained and their 
analysis support the conclusion that the FAH can help to reduce risk of developing 
diabetes by increasing abundance of the beneficial bacteria (Bifidobacterium), Treg cells, 
and decreasing levels inflammation-associated bacteria (Enterobacteriaceae), IL-17 
producing cells, and blood glucose levels. The antibiotics used in this study minimized 
result effects of FAH, emphasizing the link between gut microbiota, diet and immunity. 
 
Keywords: food at home; food away from home; gut microbiota; diabetes; antibiotic; gut 
microbiome transplantation; T regulatory cells; IL-17; glucose tolerance test 
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4.1. Introduction 
Gut microbiota dramatically affects the nutritional and immunological status of 
both humans and animals [212, 213]. Recent studies have shown that FAFH rich on fat 
and sugars are associated to dysbiosis (a microbial imbalance) and metabolic disease 
promoting [214-216], while microbiota and bacterial products founded on individuals 
with a diet high in fiber have anti-inflammatory properties [217-219]. Advances in “next 
generation” DNA sequencing have dramatically increased our capacity to study microbial 
communities associated with human body habitats (microbiota)[6, 7]. However, linking 
diet to the structure and dynamic operation of microbial communities and, more 
importantly, to the immunological status of the host has proven elusive because of 
numerous uncontrolled genetic and environmental variables and the intrinsically 
complicated nature of clinical trials. In the past, germ-free (GF) mice (animals born and 
raised without any exposure to micro-organisms) have provide an excellent system for 
controlling host genotype, diet and environmental conditions. In addition, they can be 
colonized at specific life stages with different microbial communities and thus perform 
comparative metagenomic studies of donor communities [123, 124]. However, raising 
and maintaining a GF mice colony is challenging. Hence, a broad range antibiotic 
treatment of mice is considered a viable alternative and has been successfully used 
elsewhere. Antibiotics can be administered by either oral or intraperitoneal route [125-
127]. However, extrapolating results obtained in mice to humans is difficult because most 
bacterial genera and species found in mice are different than those found in humans 
[220]. Therefore, to develop an applicable mouse model, we propose to transplant human 
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fecal microbiota into antibiotic and non-antibiotic treated C57BL/6 mice. Once a stable 
“human-like” gut community is formed, these recipient animals will be evaluated for his 
resistance to develop metabolic disease, such as diabetes. We believe this unique model 
will allow us to unequivocally determine the effects of the diet on the microbial 
community and link it to the etiology of several metabolic disorders. 
The objective of this study is to evaluate effects of food at home (FAH) and food 
away from home (FAFH) on human gut microbiota. In addition, to study whether the 
FAH-induced microbial and immunity changes can protect mice against diabetes. The 
results obtained and their analysis support the conclusion that the FAH can help to reduce 
risk of developing diabetes by increasing abundance of the beneficial microbial species, 
T regulatory cells, and decreasing IL-17 producing cell populations and blood glucose 
levels. 
4.2. Materials and Methods 
4.2.1. Human study participants and diets 
Twelve healthy male, college student participants, were recruited for the study 
and assigned in a chronological order to the FAH group or FAFH group. FAH group 
(n=6) followed food prepared at home for the duration of the study (e.g., vegetables, 
fruits, nuts, seeds, legumes, brown rice, whole wheat breads, buttermilk, herbs, spices, 
fish, poultry, eggs, yogurt, seafood and extra virgin olive oil). Additionally, avoiding 
certain foods (e.g., soft drinks, added sugars, processed meat, refined grains, refined oils 
and other highly processed foods, fast food restaurants and frozen meals). The FAFH 
group (n=6) were the opposite of FAH and consumed at least 10 meals a week from 
national fast food chains, daily for two weeks (Table 4-S1). All subjects gave their 
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informed consent for inclusion before they participated in the study. The study was 
approved by the SDSU IRB (Approval number: IRB-1512010). 
Days Restaurant Chains Typical Meal Calories 
Wednesday 
2/10/2016 
McDonald's Big Mac, large portion of French 
fries, large Coca Cola 
1330 calories 
Thursday 
2/11/2016 
Domino's Italian Sausage & Pepper Trio 
Pizza, large Coca Cola 
1410 calories 
Friday 
2/12/2016 
Burger King Triple Whopper Sandwich, large 
Coca Cola 
1310 calories 
Saturday 
2/13/2016 
McDonald's Big Mac, large portion of French 
fries, large Coca Cola 
1330 calories 
Sunday 
2/14/2016 
Domino's Italian Sausage & Pepper Trio 
Pizza, large Coca Cola 
1410 calories 
Monday 
2/15/2016 
Burger King Triple Whopper Sandwich, large 
Coca Cola 
1310 calories 
Tuesday 
2/16/2016 
McDonald's Big Mac, large portion of French 
fries, large Coca Cola 
1330 calories 
Wednesday 
2/17/2016 
Domino's Italian Sausage & Pepper Trio 
Pizza, large Coca Cola 
1410 calories 
Thursday 
2/18/2016 
Burger King Triple Whopper Sandwich, large 
Coca Cola 
1310 calories 
Friday 
2/19/2016 
McDonald's Big Mac, large portion of French 
fries, large Coca Cola 
1330 calories 
Saturday 
2/20/2016 
Domino's Italian Sausage & Pepper Trio 
Pizza, large Coca Cola 
1410 calories 
Sunday 
2/21/2016 
Burger King Triple Whopper Sandwich, large 
Coca Cola 
1310 calories 
Monday 
2/22/2016 
McDonald's Big Mac, large portion of French 
fries, large Coca Cola 
1330 calories 
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Tuesday  
2/23/2016 
Domino's Italian Sausage & Pepper Trio 
Pizza, large Coca Cola 
1410 calories 
Table 4-S1. Characteristics of FAFH group, including days of intervention, list of 
restaurant chains, typical meal, and calories. 
4.2.2. Dietary assessments 
At the study period, subjects were provided most of their food and instructed to 
record the contents of their daily intake for two weeks. Each subject’s daily intakes of 
energy, macronutrients, and other nutrients were calculated from the food record and 
estimated by Food Processor Nutritional Analysis Pro version 11.4 (ESHA Research). 
4.2.3. Animals, Antibiotic, fecal transplant, and diabetes inducing treatments 
70-female 6-8-weeks old C57BL/6 mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME). Upon arrival they were randomly grouped and keep in 
SPF filter cages and sterile bedding. Mice were fed standard low fat, plant 
polysaccharide-rich (LF/PP) diet ad libitum, and corresponding mice were treated with a 
broad range of antibiotic (Vancomycin 5mg/ml, Neomycin 10 mg/ml, Metronidazole 10 
mg/ml, and Amphotericin-B 0.1 mg/ml) by oral gavage, daily for two weeks. In addition, 
water flasks were supplemented with 1g/L of ampicillin, to assure a consistent and 
efficient bacterial depletion [127]. Afterward, mice were colonized with fecal samples 
obtained from the human volunteers [221]. In order to reduce genetic variability, fecal 
samples within the same group were pooled, diluted in PBS (1g in 10 ml) and introduced 
by oral gavage (0.2 ml) into each recipient mice. Fecal samples were collected from the 
mice before and 24h after colonization and weekly after that. One week later diabetes 
were induced with streptozotocin (STZ), a compound that induces diabetes by inhibiting 
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insulin production on pancreatic β-cells [222] (Table 4-1) (Figure 4-1). Body weight was 
measured weekly, using top-loading balances with 0.01 g precision. The mice 
experiments were performed at the Animal Research Wing (ARW) facilities under the 
supervision of Michel Mucciante, DVM. The South Dakota State University Institutional 
Care and Use Committee approved the protocols and maintenance of the animals 
(IACUC Protocol number 15-094A). 
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Treatment Group 
1 
Group 
2 
Group 
3 
Group 
4 
Group 
5 
Group 
6 
Group 
7 
Group 
8 
Antibiotic 
cocktail 
- - - - + + + + 
Fecal 
Transplant 
- FAH FAFH - - FAH FAFH - 
Experiment
al condition 
Diabete
s 
Diabete
s 
Diabete
s 
- Diabete
s 
Diabete
s 
Diabete
s 
- 
Number of 
mice 
10 10 10 5 10 10 10 5 
 
Table 4-1. Treatment groups and Experimental Design 
  
 
 
Figure 4-1. Time line of the experimental treatments
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4.2.4. Flow cytometry and Cell preparation 
Spleen tissues were collected from mice for the intracellular and external staining. 
The red cells was removed by ACK lysing buffer. The splenic cell suspension was 
stimulated and cultured for 5 h with leucocyte activation cocktail at 37 °C. Afterward, the 
cell was stained with FITC-CD4 and APC-CD25 antibodies (eBioscience, San Diego, 
CA) for 20 min at 4 °C. Then, cells were washed with FACS staining buffer (FB) (PBS 
containing 2% FCS and 0.02% NaN3) (BD PharMingen). For intracellular staining, cells 
were fixed and permeabilized using solution kit with BD GolgiStop™ (Cat. No. 554715), 
cells were incubated with rat anti-mouse IL-17A and rat anti-mouse Foxp3 antibody at 
4 °C for 30-60 min, in dark condition. Then, the cells were washed and re-suspended in 
FB and acquired in a flow cytometer instrument. Data was analyzed using BD CSampler 
Software, (BD Biosciences, Mountain View, CA, USA). 
4.2.5. Glucose Tolerance Test (GTT) 
After 16-hours of fasting, GTT was performed. For the GTT, 10 mice were 
examined at each time point. Two g glucose per kg body weight was injected 
intraperitoneal. Blood glucose levels were obtained immediately before the injection (0 
min) and at 15, 30, 60, and 120 min after glucose injection. The blood samples (5-µL) 
were collected via a small incision, made at the tip of the tail vein according to the 
manufacturer’s instructions (FreeStyle glucose analyzer, Witney, Oxon, UK). 
4.2.6. DNA Extraction and Real-Time PCR Analysis 
A total of 24 human stool samples, twelve from each group (FAFH-FAH), were 
included in this study.  DNA was extracted from stool sample by using microbial DNA 
extraction method (ZR Fecal DNA MiniPrep™) as previously described by [197]. All 
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primers and nucleotide sequences used for real-time PCR are shown in (Table 4-2). PCR 
amplification was carried out by (Agilent Technologies M x 3005P qRT-PCR) in the 
following conditions: 95 °C for 10 min, followed by 40 cycles of 95 °C for 30 s, 60 °C 
for 30 s, and 72 °C for 30 s. Power SYBR Green PCR Master Mix (AB # 4367659, 
10µl for 1 reaction). Primer (16 µM/µl- 0.5 F + 0.5 R for 1 reaction) and 9µl of each 
cDNA sample. All data were analyzed by using the comparative CT 
 method [223]. As 
following: 
 
 
Table 4-2. Primer sequences for real-time PCR 
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4.2.7. Statistical analysis 
A one-way ANOVA with independent samples t-test was used for group 
comparison of the T regulatory cells, IL-17 producing cells, glucose tolerance test, and 
body weight. Unpaired t-test was used for the group comparison between FAFW and 
FAH for nutrients intake and gut microbiota. The results were expressed as means ± S.E, 
and mean differences were considered significant at p < 0.05. Data were analyzed using 
(SPSS Statistics, v. 25). 
4.3. Results 
 In this study, we evaluated effects of FAH and FAFH diets on human gut 
microbiota. In addition, we study whether the FAH diet-induced microbial changes can 
protect mice against diabetes by modulation of the immune system. Twelve participants 
were recruited in the study (6 in the FAH group and 6 in the FAFH group). The average 
age and body mass index BMI of the study participants was 26.6 years and 26.9 (kg/m2) 
respectively. No participants dropped out of the study during the two weeks intervention 
period. 
4.3.1. Estimated Nutrients Intake at FAH and FAFH Groups of Intervention 
Periods 
At the study period, subjects were provided most of their food and instructed to 
record the contents of their daily intake for two weeks. Evaluation of dietary intakes of 
the study subjects through the study revealed no significant variations in calories, 
carbohydrates, and cholesterol intakes between the two groups (Table 4-3). As expected, 
due to a consumption of food prepared at home for the duration of the study, there was a 
significant increased on total dietary fiber intakes compared to FAFH group (p < 0.001). 
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In addition, there were a significant increased on the fat (p < 0.05), saturated fat 
(p < 0.004), and trans fatty acid (p < 0.03) intakes in FAFH group compared to FAH. 
Also, a significant reduction in the intakes of monounsaturated fat (p < 0.05) and 
polyunsaturated fat (p < 0.03) were observed in FAFH group compared to FAH group 
(Table 4-3). These results indicate that the FAH diet used in the study altered nutrients of 
intake, some of which can be associated with health benefits (particularly, significantly 
increased nutrients of dietary fiber and mono/polyunsaturated fat due to the FAH diet 
intervention). 
Nutrients FAH FAFH p * : FAH vs FAFH 
Calories (kcal/d) 2107 ± 97 2164 ± 50 NS 
Protein (g/d) 105 ± 12 72 ± 6 <0.05 
Carbohydrates (g/d) 269 ± 45 257 ± 14 NS 
Total Dietary Fiber (g/d) 29 ± 2 10 ± 1   <0.001 
Fat (g/d) 73 ± 10 100 ± 5 <0.05 
Saturated Fat (g/d) 20 ± 4 42 ± 4 <0.004 
Monounsaturated Fat (g/d) 17 ± 4 5 ± 4 <0.05 
Polyunsaturated Fat (g/d) 9 ± 1 2 ± 2 <0.03 
Trans Fatty Acid (g/d) 0.008 ± 0.001 1 ± 0.41 <0.03 
Cholesterol (mg/d) 328 ± 88 253 ± 29 NS 
 
Table 4-3. Estimated nutrients intake at FAH and FAFH groups of intervention periods. 
FAH, food at home; FAFH, food away from home; NS, not significant. The results are 
expressed as mean ± SE. p* Obtained from independent t-test (SPSS Statistics, v. 25). 
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4.3.2. Effect of FAFH and FAH diets on human gut microbiota 
Gut microbiota analysis was conducted using quantitative PCR with specific 
primers for Bifidobacterium and Enterobacteriaceae. The gene expression of 
Bifidobacterium was noticeably enriched after FAH intervention (Figure 4-2A), while 
the Enterobacteriaceae showed a decreasing trend after FAH intervention (Figure 4-2B). 
Our study indicates that short-term (2 weeks) FAH intervention results in modulation of 
the gene expression, accompanying by an increase in beneficial bacteria 
(Bifidobacterium) and a decrease in inflammation-associated bacteria 
(Enterobacteriaceae). 
 
Figure 4-2. Mean fold change of gene expression was calculated using the comparative 
CT 
 method (2ΔΔCt) between the intervention group, for Bifidobacterium (A), and 
Enterobacteriaceae (B). The results are expressed as mean ± SE. Unpaired t-test was 
used for the group comparison (SPSS Statistics, v. 25).  
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4.3.3. Effect of FAFH and FAH diets on Gp49b, 2B4, Reg3b, Ptgs2, Cxcr3, Tnfa, 
and Il6 parameters 
Parameter analysis was conducted using quantitative PCR with specific primers 
for Gp49b, 2B4, Reg3b, Ptgs2, Cxcr3, Tnfa, and Il6. The results attempt to confirm the 
effect of FAFH and FAH diets on this parameters, such a links of this parameters have 
been incorporated in health and diseases. The quantity of Gp49b, 2B4, Reg3b, and Ptgs2 
were significantly higher in the FAFH than that in FAH subjects (Figure 4-3. A, B, C, 
and D) (p=0.01) (p=0.03) (p=0.05) (p=0.04) respectively. While the level of Cxcr3 and 
Tnfa were significantly higher in the FAH group compared to the FAFH (Figure 4-3. E 
and F) (p=0.05) (p=0.01) respectively. No significant difference was perceived on fold 
change of Il6 between the FAFH and FAH subjects, even though this fold change was 
relatively abundant in the FAFH group compared to the FAH group (Figure 4-3G). 
These results indicate that the FAH diet used in the study altered gene expression of 
parameters, some of which can be associated with health benefits (particularly, 
significantly decreased parameters of Glycoprotein (Gp49b), Regenerating Islet-Derived 
3 Beta (Reg3b), and Prostaglandin-Endoperoxide Synthase 2 (Ptgs2) due to the FAH diet 
intervention). 
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Figure 4-3. Mean fold change of gene expression was calculated using the comparative 
CT 
 method (2ΔΔCt) between the intervention group, for Gp49b (A), 2B4 (B), Reg3b (C), 
Ptgs2 (D), Cxcr3 (E), Tnfa (F), and Il6 (G). The results are expressed as mean ± SE. 
*p < 0.05. Unpaired t-test was used for the group comparison (SPSS Statistics, v. 25).  
4.3.4. Effect of CD4+CD25+Foxp3+ T regulatory cells 
We here studied and compared whether production of CD4+CD25+Foxp3+ T 
regulatory cells can be influenced by antibiotic or non-antibiotic treatment, diabetes, FAT 
and FAFH diet. T regulatory cells are a subpopulation of T cells which have a role in 
suppressing or controlling other cells, to prevent autoimmune disease [224, 225]. The 
results obtained indicate that there were no statistically significant differences between 
the groups of (Control, Antibiotic + Fecal Transplant FAH + Diabetes, and Antibiotic + 
Fecal Transplant FAFH + Diabetes) (Figure 4-4A). On the other hand, the percentage of 
CD4+CD25+Foxp3+ T regulatory cells was significantly increased in Fecal Transplant 
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FAH + diabetes group compared to Fecal Transplant FAFH + diabetes (p=0.009). Also, 
from Control compared to Fecal Transplant FAH + diabetes and Fecal Transplant FAFH 
+ diabetes group (p=0.01) (p=0.001) respectively (Figure 4-4B). The findings obtained 
demonstrate that FAH diet is effective for increasing the levels of CD4+CD25+Foxp3+ T 
regulatory cells, but not in mice treated with antibiotic. 
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Figure 4-4. Percentage of Foxp3+ cells within CD4+CD25+ T cells in each Control, Fecal 
Transplant FAH + Diabetes, and Fecal Transplant FAFH + Diabetes groups (n = 10) is 
shown. For antibiotic (A) and non-antibiotic treatment groups (B). The results are 
expressed as mean ± SE. A one-way ANOVA with independent t-test was used for the 
group comparison (SPSS Statistics, v. 25).
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4.3.5. IL-17 production 
We then studied and compared whether production of IL-17 cells can be 
influenced by antibiotic or non-antibiotic treatment, diabetes, FAH and FAFH diet. “IL-
17 cells are CD4+ T-helper cells that produce IL-17 family cytokines and other 
inflammatory cytokines. IL-17 producing cells are implicated in chronic inflammation 
and are considered to drive some autoimmune diseases”[226]. The results obtained 
indicate that there were no statistically significant differences between the groups of 
(Control, Antibiotic + Fecal Transplant FAH + Diabetes, and Antibiotic + Fecal 
Transplant FAFH + Diabetes) (Figure 4-5A). On the other hand, the percentage of IL-17 
cells was significantly decreased in Fecal Transplant FAH + Diabetes group compared to 
Control, while Fecal Transplant FAH + diabetes group pointed to a decreasing trend in 
IL-17 cells percentage compared to Fecal Transplant FAFH + Diabetes group (Figure 4-
5B). The findings obtained demonstrate that FAH diet is effective for decreasing 
production of IL-17 cells, but not with mice treated with antibiotic. 
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Figure 4-5. Percentage of IL-17 cells in each Control, Fecal Transplant FAH + Diabetes, 
and Fecal Transplant FAFH + Diabetes groups (n = 10) is shown. For antibiotic (A) and 
non-antibiotic treatment groups (B). The results are expressed as mean ± SE. A one-way 
ANOVA with independent t-test was used for the group comparison (SPSS Statistics, v. 
25).  
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4.3.6. Glucose Tolerance Test (GTT) 
Blood glucose levels were obtained immediately before the injection (0 min) and 
at 15, 30, 60, and 120 min after glucose injection. After the intraperitoneal injection of 
glucose, blood glucose levels were increased in each treatment group. At 15 min, the 
blood glucose level was significantly lower in the Fecal Transplant FAH + diabetes group 
than in the Fecal Transplant FAFH + diabetes group (p=0.01). In addition, it was also 
significantly lower in the Fecal Transplant FAH + diabetes group than in Control and 
Fecal Transplant FAFH + diabetes groups at 30 min (p=0.03) (p=0.02) respectively 
(Figure 4-6A). On the other hand, the blood glucose levels of the group treated with 
antibiotic did not significantly differ between the groups (Figure 4-6B). The findings 
obtained demonstrate that FAH diet is effective for decreasing blood glucose levels, but 
not with mice treated with antibiotic. 
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Figure 4-6. Glucose tolerance test in each Control, Fecal Transplant FAH + Diabetes, 
and Fecal Transplant FAFH + Diabetes groups (n = 10) is shown. For non-antibiotic (A) 
and antibiotic treatment groups (B). The results are expressed as mean ± SE. A one-way 
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ANOVA with independent t-test was used for the group comparison (SPSS Statistics, v. 
25). 4.3.7. Body Weight and Days of Intervention 
Body weight was measured weekly, using top-loading balances with 0.01 g 
precision. As seen in figure 4-7, there were no significant difference on the body weight 
between the groups treated and not treated with antibiotic (Figure 4-7A) (Figure 4-7B). 
However, the body weight gain of the Fecal Transplant FAH + Diabetes group exhibited 
a decreasing trend at day 22. 
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Figure 4-7. Body weight in each Control, Fecal Transplant FAH + Diabetes, and Fecal 
Transplant FAFH + Diabetes groups (n = 10) is shown. For non-antibiotic (A) and 
antibiotic treatment groups (B). The results are expressed as mean ± SE. A one-way 
ANOVA with independent t-test was used for the group comparison (SPSS Statistics, v. 
25).
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4.4. Discussion 
 The study was designed to evaluate the effects of food at home (FAH) and food 
away from home (FAFH) on human gut microbiota. In addition, to study whether the 
FAH diet-induced microbial and immunity changes can protect mice against diabetes 
following the transplantation of human fecal microbiota into antibiotic and non-antibiotic 
treatment mice. While FAH diet have been shown to improve markers of metabolic 
syndrome and gut microbiota [227, 228]. However, this study was comprehensively 
evaluating effects of FAH and FAFH diets in gut microbiota, immune function, body 
weight, diabetes developing in antibiotic and non-antibiotic treatment mice. 
An important finding of the study is that the FAH group resulted in a noticeable 
increase in abundance of Bifidobacterium strains in the gut after a 2-weeks intervention. 
It has been stated that some strains of Bifidobacterium can be referred as healthy gut 
microbiota along with anti-diabetes agents [229, 230]. Furthermore, Enterobacteriaceae 
family was noticeably decreased after the FAH diet intervention (see Figure 2-2). 
Previous studies have stated that these family are associated with inflammation-driven 
bacterial dysbiosis and positively correlated with diabetes [231-233]. Therefore, the study 
confirmed that short-term (2 weeks) FAH intervention results in an increase in beneficial 
bacteria (Bifidobacterium) and a decrease in pro-inflammatory bacteria 
(Enterobacteriaceae). 
Dietary patterns containing FAH diet are now broadly recognized to be critical for 
protection against various diseases with an inflammatory nature. In contrast, FAFH diet 
are recognized to apply various harmful effects [234, 235]; including its metabolic and 
inflammatory related alterations in CD4+CD25+Foxp3+ T regulatory cells, and IL-17 
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[236]. Therefore, we examined the possible alterations caused by FAH diet to this 
populations and there resistance for development of diabetes. Higher percentage of 
CD4+CD25+Foxp3+ T regulatory cells were observed in Fecal Transplant FAH + diabetes 
group compared to Fecal Transplant FAFH + diabetes (see Figure 4-4B). In the Fecal 
Transplant FAH + diabetes group, increasing percentage of CD4+CD25+Foxp3+ T 
regulatory cells was associated with decreasing blood glucose levels (see Figure 4-6A). 
However (and somewhat paradoxically), higher percentage of CD4+CD25+Foxp3+ T 
regulatory cells at control group compared to Fecal Transplant FAH + diabetes and Fecal 
Transplant FAFH + diabetes were also observed (see Figure 4-4B). The administration of 
diabetes (STZ) and the effect of longstanding hyperglycemia can promote a strong 
inflammatory progression in the islets which is toxic to beta cells. Thus, increasing the 
number of T regulatory cells in the spleen were as a results of controlling damage of the 
tissue [237]. The role of IL-17 producing cell in FAH diet has not been totally examined. 
Thus, our data point out an increased on the frequencies of IL-17 cell in control group 
compared to Fecal Transplant FAH + diabetes; which also involve in the pathogenesis of 
diabetes. 
In the present study, the FAH diet used in the study altered gene expression of 
parameters, some of which can be associated with health benefits (particularly, 
significantly decreased parameters of Gp49b, Reg3b, and Ptgs2 due to the FAH diet 
intervention)[238-240]. An interesting finding was the reduced glucose intolerance in 
FAH fecal transplant, Gp49b, Reg3b, and Ptgs2 –deficient mice. Therefore, Gp49b, 
Reg3b, and Ptgs2 might be important for the development of type 2 diabetes which 
requires further investigation. 
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Our data point out that antibiotic administration minimized result effects of FAH 
diet on both CD4+CD25+Foxp3+ T regulatory cells, IL-17 production, and glucose 
tolerance test, compared to those groups of non-treated with antibiotic, such an antibiotics 
can change the population or balance of composition and more compromise mucosal 
immunity of the gut microbiota [241]. 
Evaluation of dietary intakes of the study subjects through the study revealed a 
significant variations between the two groups (Table 4-3). As expected, due to a 
consumption of food prepared at home FAH, there was a significant increased on total 
dietary fiber intakes compared to FAFH group. These results indicate that the FAH diet 
used in the study altered nutrients of intake, some of which can be associated with health 
benefits (particularly, significantly increased nutrients of dietary fiber due to the FAH 
diet intervention). Importantly, these dietary fiber have been previously shown to produce 
short-chain fatty acids (SCFAs), a bacterial fermentation product of dietary fiber, 
recognized to have wide-ranging effects on maintenance of health and host physiology 
[199-201]. 
The design of the study has allowed us to detect important effects of FAH vs. 
FAFH-induced changes on gut microbiota and immunological status in diabetes in the 
relatively limited number of participants in this study. However, the used of dietary 
records are affected by error and has limitation “due mainly to the tendency of subjects to 
report food consumption close to those socially desirable. Further problems are related to 
the high burden posed on respondents. It can also influence food behavior in respondents 
in order to simplify the registration of food intake and some subjects can experience 
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difficulties in writing down the foods and beverages consumed or in describing the 
portion sizes” [242]. 
The results obtained and their analysis support the conclusion that the FAH can 
help to reduce risk of developing diabetes by increasing abundance of the beneficial 
bacteria (Bifidobacterium), T regulatory cells, and decreasing in inflammation-associated 
bacteria (Enterobacteriaceae), IL-17 producing cell populations, and blood glucose 
levels. The antibiotics used in this study minimized result effects of FAH diet. Further 
additional studies using germ-free mice are needed to better understand the role of gut 
microbiota in the modulation of the immune system and its contribution to inflammation 
and autoimmunity diseases. 
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CHAPTER 5. General Discussion 
The rising prevalence of obesity and metabolic disorders and its harmful health 
consequences are of increasing global concern [1, 2]. The health effects of being 
overweight and obese are not without controversy [243, 244], but large pooling studies 
have shown increased risks for cardiovascular diseases, diabetes, cancers and chronic 
kidney diseases[245, 246]. Although public health campaigns and an increasingly health-
conscious general population has succeeded in slowing the growth rate of obesity in 
developed countries, much more has to be done in order to reach the WHO target of 
halting the rise in obesity by 2025. To date, there is not a single country with well-
documented downwards trends in obesity rates. Therefore, rigorous data-based plans 
combining a healthy diet with the promotion of a more active lifestyle are needed in order 
to be evaluated and translated into national obesity control programs. 
From a metabolic point of view, obesity is the consequence of a prolonged 
imbalance between energy intake and expenditure caused by a very complex interplay 
between genetics, nutrition and environmental factors [247, 248]. Recent studies have 
shown that gut microbiota plays a critical role in the pathogenesis of obesity and 
associated diseases [249]. Such a link was first suggested after observing that 
colonization of lean mice with cecal microbiota from obese mice resulted in a greater 
increase in body fat when compared with microbiota from lean mice [18]. Subsequent 
studies in both mice and humans confirmed that obesity was accompanied by an altered 
gut microbiota [153, 250-252]. Therefore, the gut microbiota has become a target for 
obesity and metabolic disease prevention. Indeed, data from both experimental and 
clinical studies suggest that modulation of gut microbiota through administration of 
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probiotics (normally Lactobacillus or Bifidobacterium) may be an effective strategy to 
treat metabolic diseases, although other studies failed to find a correlation between 
probiotic supplements and an improved health status [253]. Besides probiotics, the gut 
microbiota can be modulated through administration of prebiotics, food ingredients that 
resist degradation in the upper digestive tract and selectively enhance the growth and/or 
activity of one or few resident bacteria and can improve insulin sensitivity, lipid 
metabolism and low-grade chronic inflammation [254, 255]. Consequently, synbiotics, or 
the combination of both pre and probiotics, have the potential to induce a more 
substantial effect on gut microbiota and host health and are therefore the focus of a big 
research effort [256]. 
Probiotic bacteria have often been assessed as dietary supplements or in dairy 
products, such as yogurt or kefir [115, 116]. We believe that because of its nutritional 
values and longer shelf life, fermented cheese would be an ideal vector for the delivery of 
probiotics. Cheese is a good matrix for transferring probiotic bacteria into the 
gastrointestinal tract, due to the buffering capacity of the milk proteins which will protect 
the cells during transit; this is mainly due to their higher fat content and denser structure 
that may protect the bacteria against the acidic environment of the gastrointestinal tract 
[117-119]. 
It was demonstrated that whole grain diet can decreased risk of numerous 
lifestyle-associated diseases including type 2 diabetes, for the reason that “microbial 
degradation of whole grains, rich in dietary fibers, leads to production of short-chain fatty 
acids, which may exert beneficial effects on the host metabolism” [257]. However, it is 
not been thoroughly investigated to what extent beneficial effects of whole grain and 
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food at home consumption are associated with the gut microbiota and immunological 
status. 
In view of the potential effects of diet, prebiotics, and probiotics on gut 
microbiota in obesity and metabolic disorders, the main hypothesis tested in these studies 
was that the whole grain diet, dairy products, pre and probiotics will modulate gut 
microbiota by increasing abundance of the beneficial microbial species and the 
supplement may also have beneficial effects on body composition, immune system, and 
metabolic parameters in obesity. The aims of this dissertation were (1) to evaluate effects 
of the synbiotic supplement containing Bifidobacterium and Lactobacillus strains on the 
human-gut microbiota in relation to changes in body composition and metabolic 
biomarkers in obesity, (2) to characterize the effect of dairy products (cow, goat, and 
camel milk and fermented cheese and yogurt originated from cow milk and containing 
the well-established probiotic Clostridium butyricum) on taxonomic composition and 
relative abundance of the mouse gut microbiota and body weight, (3) to study the effects 
of food at home and food away from home diets on human gut microbiota. In addition, to 
study whether the food at home-diet-induced microbial and immunity changes can 
protect mice against diabetes. 
The data presented in Chapter 2 indicate that weight loss in human subjects 
participating in a high-protein, low-carbohydrate, energy-restricted eating weight loss 
program is accompanied by changes in gut microbiota that can be associated with 
increased genotoxicity [144]. The synbiotic used in this study modulated the human gut 
microbiota by increasing abundance of the microbial species that can be considered to be 
of benefit to their host; it was also associated with positive effects on metabolic 
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parameters in obesity. A combination of the four strains of Bifidobacterium and 
Lactobacillus acidophilus in the synbiotic supplement resulted in a significant increase in 
abundance of these probiotic genera in the gut after a 3-month intervention. 
Bifidobacterium is largely considered a positive member of the microbial community and 
furthermore, there has been some association with anti-obesity effects [162, 166, 167]. In 
addition to this, further modulation of the microbiota was observed, for example, 
Prevotella and Gardnerella genera were significantly decreased after the synbiotic 
intervention. Previous studies have reported that these genera are associated with chronic 
inflammatory conditions and positively correlated with obesity [168-170]. Therefore, the 
reduction in these genera could help to modulate the balance to improve metabolism 
within the host. Special caution is warranted when analyzing the data referring to 
Prevotella, a complex genus linked both to health and disease and maybe influenced by 
race/ethnicity [171]. However, statistically significant differences in the community 
composition of gut microbiota between groups (synbiotic vs. placebo) and time points 
(end vs. beginning of trial) using parameters of alpha-diversity and beta-diversity were 
not observed. Our data is compatible with a recent study that did not found a relationship 
between severe caloric restriction and changes in alpha-diversity[172]. In addition, 
correlation and regression analyses did not indicate statistically significant or apparently 
beneficial associations between species contained in the synbiotic supplement 
(Bifidobacterium and Lactobacillus) and body composition parameters, including at the 
end of synbiotic intervention. Interestingly, the changes over time in body mass, BMI, 
waist circumstance, and body fat mass demonstrated a positive correlation trend with 
Bifidobacterium abundance in the synbiotic group, while changes in body fat mass were 
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negatively correlated with Lactobacillus abundance in the placebo group. However, 
positive associations between relative abundance of Bifidobacterium and several body 
composition parameters appear to point to the unfavorable role of these bacteria in 
promoting weight loss, although any potential benefits of this genera could be masked by 
the high-protein diet used in the study. High protein intake induces proteolytic 
fermentation in the gut with synthesis of compounds that have been implicated in the 
development of obesity and metabolic syndrome and modulating the gut microbiota [140-
142, 173] and the production of toxic metabolites [174]. Several studies have also found 
that an increase in Bifidobacterium and Lactobacillus abundance is correlated with both 
pro- and anti-obesity effects in obese human subjects [175, 176], thus complicating the 
interpretation of the results. Individual differences in energy extraction may contribute to 
explain the observed differences [177]. Additionally, Bifidobacterium have been linked 
with improved barrier function in overweight individuals, thus adding a potential 
beneficial mechanism of action [81]. Therefore, more studies are needed to fully 
understand the observed divergences and correctly identify human subpopulations 
susceptible to benefit from synbiotic intervention. 
Regression analysis performed to correlate microbial abundance of species 
contained in the synbiotic supplement with biomarkers of obesity found a novel 
significant association between a decrease over time in HbA1C percentage and an 
increase in Lactobacillus abundance, particularly in the synbiotic group. This is an 
important observation because it demonstrates the beneficial effect of increasing 
Lactobacillus abundance on potentially reducing blood glucose levels. Negative 
associations between Megasphaera abundance and Eubacterium ruminantium abundance 
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with HbA1C levels were observed in the synbiotic group at the end of trial. Eubacterium 
ruminantium are xylanolytic bacteria (i.e., producing xylanase following dietary fiber 
fermentation) and Megasphaera bacteria utilize lactate [178], which can underlie 
potential relationship of these species to decreasing blood glucose levels [179, 180]. 
However, within the trial following the synbiotic a decrease in Megasphera was 
observed, an increase in Eubacterium ruminantium. This could imply that the synbiotic 
intervention and associated microbial changes could be linked to maintaining a normal 
blood glucose levels in obesity. 
It should also be considered that the microbial shifts observed in this study may 
be associated with a positive impact on microbial fermentation within the large intestine. 
Whilst the microbial changes observed following synbiotic intervention included an 
increase in Ruminococcus, a genera known to produce butyrate. Butyrate is a short chain 
fatty acid that provides and energy source for the colonocytes, as a histone deacetylase 
inhibitor this SCFA is linked to anti-cancer effects, hence could offer protection against 
some of the metabolites that are produced within a high protein diet. SCFA’s have also 
recently been associated with protection against type 1 diabetes [181]. In addition to this 
lactobacilli and bifidobacteria are associated with positive effects of colonic health and 
following synbiotic intervention have been associated with reducing fecal water 
genotoxicty, which is considered a biomarker for colon cancer [182]. Therefore, whilst 
within the weight-loss diet employed the synbiotic treatment may have had a limited 
impact on the weight-loss parameters, it is possible that the changes in the microbiota 
could help to reduce detriments associated with a high protein diet. 
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Manipulation of the gut microbiota through dietary intervention and probiotic 
supplements can be a promising strategy for the prevention and treatment of metabolic 
syndrome and obesity. Therefore, data presented in Chapter 3 demonstrated that gut 
microbiota enrichment can be achieved via consumption of camel milk, as compared with 
cow and goat milk. In addition, the significant gut microbiota enrichment was observed 
in mice supplemented with the probiotic cow cheese, as compared with the probiotic cow 
and goat yogurt. To our knowledge, this is the first study that compared the effects of 
supplementation with dairy products originating from different animals on the gut 
microbiota composition, particularly, the study of camel milk and fermented cheese. The 
present study indicated that, when compared with mice fed with cow milk, mice fed a 
diet supplemented with camel milk demonstrate a decrease in body weight gain 
accompanied by characteristic changes in gut microbiota, including an increase in order 
Clostridiales and genus Anaerostipes. Importantly, these bacteria have been previously 
shown to produce short-chain fatty acids (SCFAs) a bacterial fermentation product of 
dietary fiber, recognized to have wide-ranging effects on maintenance of health and host 
physiology [199-201]. We also found a decreased abundance of Peptostreptococcaceae 
bacteria in the camel milk group. Importantly, species in this family are positively 
associated with obesity and inflammation [202-204]. The health benefits of camel milk 
may be partly underlined by its functioning as prebiotic. Camel milk has a high overall 
nutritional value and high heat stability in the process of preservation of raw milk by 
pasteurization [205, 206]. The induction of the SCFAs producing gut bacteria via 
consumption of camel milk may lead to development of nutritional strategy for weight 
loss and the prevention and treatment of obesity. 
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Surviving passage over the host’s gastrointestinal tract is a critical event for any 
probiotic. In this regard, we observed that the total significant richness in the dataset were 
16 OTUs for the probiotic cow yogurt group vs. the cow yogurt, 13 OTUs for the 
probiotic goat yogurt group vs. the goat yogurt group, and 30 OTUs for the probiotic cow 
cheese group vs. the cow cheese group. These results indicate that the probiotic 
supplement used in the study modified relative abundance of gut bacteria, some of which 
can be associated with health benefits (particularly, significantly increased abundance of 
order Clostridiales due to the probiotic intervention). Therefore, cheese appear to be a 
good matrix for transferring probiotic bacteria into the gastrointestinal tract, probably, 
due to the high buffering capacity of milk proteins which will protect the microbial cells 
during transit (high fat cheese content and dense product structure may also protect the 
bacteria against the acidic environment in the gastrointestinal tract [117-119]). 
Clostridium butyricum supplementation triggered a shift in body weight gain with a 
significant decrease in probiotic cow cheese group compared with the probiotic goat and 
cow yogurt groups. We also found that the addition of this probiotic to cow cheese 
improves gut microbiota manifesting in an increase in the relative abundance of order 
Clostridiales, family Ruminococcaceae, and Lachnospiraceae. These bacteria have been 
previously shown to produce butyrate [207, 208]. Butyrate (one of the main SCFAs) may 
be protective from developing of obesity and metabolic disorder [181, 209]. Additionally, 
this probiotic in cheese was associated with a significant reduction on the family 
Erysipelotrichaceae and genus Coprococcus. The Erysipelotrichaceae  abundance is high 
in obese individuals [210]. Furthermore, the relative abundance of Coprococcus is 
increased by high-fat diet [211]. These are important considerations because they suggest 
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the beneficial effect of the probiotic cow cheese supplementation on maintaining normal 
body weight gain and facilitating weight loss in obesity. 
The data presented in Chapter 4 indicate that the food at home, can help to 
reduce risk of developing diabetes by increasing abundance of the beneficial bacteria 
(Bifidobacterium), T regulatory cells, and decreasing in inflammation-associated bacteria 
(Enterobacteriaceae), IL-17 producing cells, and blood glucose levels. Importantly, the 
FAH diet used in the study altered gene expression of novel parameters, some of which 
can be associated with health benefits (particularly, significantly decreased parameters of 
Gp49b, Reg3b, and Ptgs2 due to the FAH diet intervention)[238-240]. An interesting 
finding was the reduced glucose intolerance in FAH fecal transplant, Gp49b, Reg3b, and 
Ptgs2 –deficient mice. Consequently, Gp49b, Reg3b, and Ptgs2 might be important for 
the development of type 2 diabetes which requires further investigation. Our data also 
point out that antibiotic administration minimized result effects of FAH diet on both 
CD4+CD25+Foxp3+ T regulatory cells, IL-17 producing cells, and glucose tolerance test, 
compared to those groups of non-treated with antibiotic, such an antibiotics can change 
the population or balance of composition and more compromise mucosal immunity of the 
gut microbiota [241]. Further additional studies using germ-free mice are needed to better 
understand the role of gut microbiota in the modulation of the immune system and its 
contribution to inflammation and autoimmunity diseases. 
In summary, this dissertation explores a scope of studies on the effects of diet on 
gut microbiota and health outcomes including obesity and metabolic disorders taking into 
perspective diets such as food at home, dairy products, high-protein, low-carbohydrate, 
prebiotic and probiotic. The main outcome of our studies is identification of an effective 
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and novel approach for the prevention and treatment of obesity and metabolic disorders 
that is based on modulating the human/mouse gut microbiota and increasing abundance 
of the microbial species that can be considered to be of benefit to their immune system 
and host.  
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APPENDIX 
Table 2-S3. Body composition parameters, including DXA scans data. A and B before 
sample numbers indicate the synbiotic and placebo groups, respectively. 
Treat
ment 
Timep
oint 
Subj
ect 
Gen
der 
A
ge 
HbA1C_p
ercent 
Body_m
ass_kg 
BMI_kg_
per_m2 
WC
_cm 
Body_Fat_
percent 
Synbi
otic 
EndOf
Trial 
A1 F 48 4.5 63.8 26.4 97 33.9 
Synbi
otic 
EndOf
Trial 
A10 F 66 5.5 70.3 28.4 93 41.6 
Synbi
otic 
EndOf
Trial 
A11 M 45 4.9 82.5 26.9 102 NA 
Synbi
otic 
EndOf
Trial 
A3 F 37 4.8 104 41.9 120 48.5 
Synbi
otic 
EndOf
Trial 
A4 F 47 4.3 80.8 30.4 94 44.4 
Synbi
otic 
EndOf
Trial 
A5 M 43 5.3 92.5 27.7 104 29.3 
Synbi
otic 
EndOf
Trial 
A6 F 42 5.2 91 34.5 108 47.7 
Synbi
otic 
EndOf
Trial 
A7 F 60 5.7 89.5 37.3 101 45.1 
Synbi
otic 
EndOf
Trial 
A8 M 40 5.3 78.9 27.3 96 22.6 
Synbi
otic 
EndOf
Trial 
A9 F 50 5.1 81.6 34 111 NA 
 
Place
bo 
EndOf
Trial 
B1 M 51 5.9 133 35.7 123 33 
Place
bo 
EndOf
Trial 
B10 F 79 5 77.7 27.7 105 40.3 
Place
bo 
EndOf
Trial 
B11 F 34 4.9 68 24.2 88 NA 
Place
bo 
EndOf
Trial 
B3 F 45 4.6 76.2 27.7 99 42.8 
Place
bo 
EndOf
Trial 
B4 F 39 4.9 86.6 26.9 85 38 
Place
bo 
EndOf
Trial 
B5 F 51 4.6 79.2 30 94 35 
Place
bo 
EndOf
Trial 
B6 F 39 5.2 100.6 32.8 108 41.4 
Place
bo 
EndOf
Trial 
B7 F 50 5 93.5 36.5 108 46.1 
Place
bo 
EndOf
Trial 
B8 M 22 5.3 119 32.3 115 NA 
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Place
bo 
EndOf
Trial 
B9 F 60 5.2 66.3 27.6 86 NA 
 
Treat
ment 
Timep
oint 
Subj
ect 
Gen
der 
A
ge 
HbA1C_p
ercent 
Body_m
ass_kg 
BMI_kg_
per_m2 
WC
_cm 
Body_Fat_
percent 
Synbi
otic 
Baseli
ne 
A1 F 48 5.6 66.4 27.5 98 35.6 
Synbi
otic 
Baseli
ne 
A10 F 66 5.3 84.8 34.2 106 48.5 
Synbi
otic 
Baseli
ne 
A11 M 45 5.3 93 30.3 113 NA 
Synbi
otic 
Baseli
ne 
A3 F 37 5.5 113 45.6 127 49.9 
Synbi
otic 
Baseli
ne 
A4 F 47 5.1 82.9 31.2 102 45.5 
Synbi
otic 
Baseli
ne 
A5 M 43 5.4 97.5 29.2 110 27.6 
Synbi
otic 
Baseli
ne 
A6 F 42 5.9 95.2 36.1 108 44.4 
Synbi
otic 
Baseli
ne 
A7 F 60 5.7 95.7 39.8 108 44.8 
Synbi
otic 
Baseli
ne 
A8 M 40 5.1 88.4 30.6 107 27.8 
Synbi
otic 
Baseli
ne 
A9 F 50 5 90 37.5 117 NA 
 
Place
bo 
Baseli
ne 
B1 M 51 8.2 147.4 39.6 129 31.7 
Place
bo 
Baseli
ne 
B10 F 79 4.9 78.2 27.9 106 42.3 
Place
bo 
Baseli
ne 
B11 F 34 4.8 78.7 28.1 97 NA 
Place
bo 
Baseli
ne 
B3 F 45 5.5 81.6 29.6 102 43.3 
Place
bo 
Baseli
ne 
B4 F 39 5.3 99.7 30.9 103 42.1 
Place
bo 
Baseli
ne 
B5 F 51 5.5 86.8 32.9 95 38 
Place
bo 
Baseli
ne 
B6 F 39 4.3 112 36.6 117 41.5 
Place
bo 
Baseli
ne 
B7 F 50 4.6 102.9 40.2 118 47.9 
Place
bo 
Baseli
ne 
B8 M 22 5.3 117 31.7 114 NA 
Place
bo 
Baseli
ne 
B9 F 60 5.2 72.5 30.2 88 NA 
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Treatm
ent 
Timepoi
nt 
Subje
ct 
Gend
er 
Ag
e 
Lean_Mass
_kg 
Fat_Mass
_kg 
BMC_
kg 
BLM.BMC
_kg 
Synbiot
ic 
EndOfTr
ial 
A1 F 48 40.8 21.98 1.9802
7 
42.7845 
Synbiot
ic 
EndOfTr
ial 
A10 F 66 40.9 30.31 1.7203
5 
42.6258 
Synbiot
ic 
EndOfTr
ial 
A11 M 45 NA NA NA NA 
Synbiot
ic 
EndOfTr
ial 
A3 F 37 52.95 52.37 2.6158
4 
55.5709 
Synbiot
ic 
EndOfTr
ial 
A4 F 47 43.96 36.72 1.9774
9 
45.9383 
Synbiot
ic 
EndOfTr
ial 
A5 M 43 63.95 27.78 3.0627
2 
67.0143 
Synbiot
ic 
EndOfTr
ial 
A6 F 42 46.05 44.27 2.4120
3 
48.4709 
Synbiot
ic 
EndOfTr
ial 
A7 F 60 47.37 40.76 2.3160
9 
49.6947 
Synbiot
ic 
EndOfTr
ial 
A8 M 40 59.8 18.31 2.9595
4 
62.792 
Synbiot
ic 
EndOfTr
ial 
A9 F 50 NA NA NA NA 
 
Placebo EndOfTr
ial 
B1 M 51 90.64 46.57 4.0103
9 
94.6529 
Placebo EndOfTr
ial 
B10 F 79 44.5 31.47 2.1064
6 
46.6281 
Placebo EndOfTr
ial 
B11 F 34 NA NA NA NA 
Placebo EndOfTr
ial 
B3 F 45 44.44 34.76 2.0451 46.492 
Placebo EndOfTr
ial 
B4 F 39 51.97 33.76 3.0332
8 
55.0122 
Placebo EndOfTr
ial 
B5 F 51 50.61 28.53 2.3247
1 
52.9441 
Placebo EndOfTr
ial 
B6 F 39 58.25 43.03 2.7176
4 
60.973 
Placebo EndOfTr
ial 
B7 F 50 48.9 44 2.5691
4 
51.4396 
Placebo EndOfTr
ial 
B8 M 22 NA NA NA NA 
Placebo EndOfTr
ial 
B9 F 60 NA NA NA NA 
 
Treatm
ent 
Timepoi
nt 
Subje
ct 
Gend
er 
Ag
e 
Lean_Mass
_kg 
Fat_Mass
_kg 
BMC_
kg 
BLM.BMC
_kg 
Synbiot
ic 
Baseline A1 F 48 41.38 23.93 1.9785
3 
43.3602 
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Synbiot
ic 
Baseline A10 F 66 42.5 41.58 1.7254
8 
44.2227 
Synbiot
ic 
Baseline A11 M 45 NA NA NA NA 
Synbiot
ic 
Baseline A3 F 37 54.37 56.73 2.6275
9 
57.0028 
Synbiot
ic 
Baseline A4 F 47 43.64 38.12 1.9998
8 
45.6463 
Synbiot
ic 
Baseline A5 M 43 65.33 26.08 3.0840
3 
68.4227 
Synbiot
ic 
Baseline A6 F 42 50.02 41.79 2.3707
2 
52.3916 
Synbiot
ic 
Baseline A7 F 60 50.13 42.65 2.3355
1 
52.4722 
Synbiot
ic 
Baseline A8 M 40 61.7 24.9 2.9607
3 
64.6943 
Synbiot
ic 
Baseline A9 F 50 NA NA NA NA 
 
Placebo Baseline B1 M 51 94.5 45.72 3.9495
6 
98.4542 
Placebo Baseline B10 F 79 41.6 32.1 2.1697
6 
43.7326 
Placebo Baseline B11 F 34 NA NA NA NA 
Placebo Baseline B3 F 45 44.49 35.57 2.0877
3 
46.5816 
Placebo Baseline B4 F 39 55.81 42.72 2.9912 58.8061 
Placebo Baseline B5 F 51 51.88 33.17 2.3562
6 
54.2397 
Placebo Baseline B6 F 39 62.49 46.25 2.6781
5 
65.1701 
Placebo Baseline B7 F 50 51 49.09 2.4421
6 
53.4179 
Placebo Baseline B8 M 22 NA NA NA NA 
Placebo Baseline B9 F 60 NA NA NA NA 
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Table 3-S1. Body weight (g) and time (days) measurements of mice fed diet 
supplemented with dairy products. 
 0 day 7 day 14 day 21 day 28 day 35 day 
Cow Milk 15.1 16.4 17 17.5 18.7 18.8 
14.2 15.9 16.9 17.6 18.1 19.2 
16.5 17.9 19.1 19.3 20.4 18.2 
14.6 15.9 17.1 17 18.2 19.5 
15.1 16.7 17.5 17.6 18.5 18.7 
Goat Milk 14.2 15.1 16.5 16.4 17.9 18.9 
12.6 14.6 15.4 15.8 16.3 16.9 
15.6 17.6 17.9 18.3 18.5 18.9 
15 16 16.7 17.1 17 18.1 
15.7 17.1 17.9 18.3 18.7 19.5 
Camel Milk 15.5 16.5 17.9 17.9 18.1 18.4 
15.4 16.1 17.7 17 18.1 18.4 
14.5 15.5 16.5 16.3 16.4 16.3 
16.5 17 17.9 17.4 18.2 18.6 
14.2 15.8 16.8 16.5 18.1 18.3 
Cow Yogurt 15.5 16.1 17.3 17.1 18.1 18.4 
14.8 16.1 17.1 17.1 17.1 18.2 
14.7 16.3 17.4 18.5 18.7 18.9 
16.9 17.7 18.3 20.2 19.8 20.8 
15.3 16.1 16.3 16.4 16.3 16.9 
Goat Yogurt 15.6 17.9 18.6 18.9 18.9 18.9 
15.7 16.1 17.2 17.2 18.1 18.2 
17 17.4 18.1 18.4 18.8 18.9 
17.4 17.4 18.6 18.7 19.8 20.1 
16.8 17.4 18.6 19.1 19.1 19.7 
Cow Yogurt  Pro 17 18.5 18.7 19.2 20.3 20.9 
16 16.7 17.4 17.5 18.4 18.7 
15.9 16.7 17.3 17.7 18 17.5 
17 18.1 19.4 19.5 20.5 20.7 
15.8 16.5 17.8 17.7 18.6 18.8 
Goat Yogurt Pro 17.2 17.9 19 19.2 19.3 20.3 
16.8 17.3 17.7 18.9 19.4 20.1 
17.3 18.9 19.1 19.8 20.3 19.6 
13.6 14.5 15.3 17.1 18.3 18.1 
14.3 16.1 16.9 18.5 20.1 21.1 
Cow Cheese 14.8 16.5 16.9 17.5 18.4 19.5 
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16.4 17 17.7 18.5 18.4 18.6 
15.6 15.7 16.3 17.2 17 17.4 
16.6 18.5 18.2 18.6 19.2 19.3 
15.3 16.9 16.3 17.1 17.8 19 
Cow Cheese Pro 15.1 15.5 16.5 17.3 17.3 17.9 
16.7 17.5 18.1 18.2 18.1 18.8 
14.5 15.3 16.6 17.7 17.5 18.3 
16.4 16.9 17.2 18.2 18.6 18.8 
17 17.5 18.7 18.9 18.6 19.6 
Ctrl 15.7 16.2 16.5 17.6 16.7 16.3 
15.4 15.4 17.2 17.4 17.3 16.8 
16.6 17.4 17.8 19.1 18.1 17.8 
15.5 16.4 17.3 18.4 18.4 18 
15.8 16.7 17.3 18.3 18.2 17.6 
 
 
